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Abstract 
 
 
(+)-Pancratistatin is a medicinally useful compound which has been isolated from plants 
belonging to the Amaryllidaceae plant family. The deceptively simple looking 
pancratistatin is in fact a complicated molecule; it has six contiguous stereocenters of 
which four belong to alcohol groups and the other two make up a trans B-C ring junction. 
In addition, it consists of three fused rings. The medicinal properties and the synthetic 
challenges set by pancratistatin have attracted the attentions of many synthetic groups.  
 
Herein are reported approaches to the synthesis of C-seco pancratistatin analogues. D(-)-
tartaric acid was used as the starting material as it contains two of the four stereocenters 
found in pancratistatin.  
 
Organocuprate and rhodium-catalyzed reactions were successfully employed to install 
one of the two stereocenters required for the trans B-C junction. The rhodium catalysed 
addition reactions were found to be more efficient: they were easier to set up, the work up 
was a simple filtration, high conversions and anti-selectivity were observed. The anti-
selective addition was proved by means of obtaining a crystal structure of 3-((4R,5R)-5-
(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-3-phenylpropanoic acid -                             
a carboxylic acid derivative of an addition product. 
 
Confirmation of the resulting compound, resulting from the attempted ring closure via an 
isocyanate intermediate - formed through a Curtius rearrangement of an azide - to 
complete the trans B-C junction has proved, through NMR analysis, to be inconclusive. 
Unfortunately, this result meant that the synthesis was halted one step away from the 
formation of a protected open chain pancratistatin analogue. 
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Good progress was made towards the synthesis of open chain pancratistatin analogues 
and it is said with great optimism that the analogues will eventually be made. 
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Chapter 1: Introduction 
 
1.1 The Amaryllidaceae alkaloids 
 
Historically the Amaryllidaceae plant family has always been a source of medicinally 
useful compounds; over 30 species have been used to treat cancer in ancient times. The 
use of Amaryllidaceae family plants can be traced back to the fourth century BC.  
Hippocrates of Cos used oil extracted from the daffodil Narciclasus poeticus to treat 
patients with uterine cancer. Incidentally South Africa and Andean South America is host 
to a wide variety of plants belonging to the Amaryllidaceae family.1 
 
In 1877, the first Amaryllidaceae alkaloid, lycorine 1 (Figure 1) was isolated from 
Narcissus pseudonarcissus.2 Lycorine has been shown to possess anticancer and antiviral 
activity.3 Furthermore from the bulbs of Lycoris radiate, the antineoplastics lycoricidine 
2 and narciclasine 3 (Figure 1) were isolated in 1968.4 
 
N
O
O
OH
HO
1 lycorine 2 R = H, lycoricidine
3 R = OH, narciclasine
4 R = H, 7-deoxynarciclasine
NH
O
O
OR
OH
OH
OH
NH
O
O
OR
OH
OH
OHHO
5 R = OH, (+)-pancratsistatin
6 R = H, (+)-7-deoxypancratistatin
A B
C
C-10b
 
Figure 1 Medicinally useful compounds belonging to the Amaryllidaceae family 
 
In 1984, Pettit and co-workers isolated (+)-pancratistatin 5 (Figure 1) 
from the spider lily Pancratium littoralle.5 During biological evaluation, 
pancratistatin has shown activity as an antiviral6, antiparasitic7 and 
anticancer agent.8,9,10,11 As an anti-cancer agent, pancratistatin has 
shown excellent in vitro and in-vivo activity against: leukaemia, 
pancreas, breast, lung, colon and prostate cancer cell lines.8,9 A few 
  
2 
years later, (+)-7-deoxypancratistatin 6 (Figure 1) was isolated from Haemanthus 
kalbreyeri by Ghosal and co-workers.12 As with (+)-pancratistatin, (+)-7-
deoxypancratistatin has also been shown to possess useful medicinal properties. 
 
Examining the etymology of the word pancratistatin it’s no surprise as to how 
medicinally powerful the compound is. The word pancratistatin comes from the Latin 
word pancratistatinum which means an “all-powerful breaker or stopper”.13 The plant 
from which pancratistatin was isolated, Pancratium littoralle, translates from latin as “all 
powerful from the shore of a lake”. The Latin word pancratium is the offspring of the 
Greek word pankration which means “victory by any and all means”. The word, 
pankration, was used to describe ancient Greek wrestling matches which were fought to 
the death or until total surrender of one of the opponents – gouging and biting were 
forbidden from these contests!  
 
1.2 Medicinal properties of pancratistatin and 7-deoxypancratistatin 
  
Cancer still plagues modern civilisation and despite enormous efforts to cure the disease 
there is still no single cure which effectively singles out cancerous cells. Currently 
Western medicine predominately makes use of gentotoxic treatments such as 
chemotherapy, radiotherapy and immunotherapy. These treatments involve damaging the 
DNA of cancerous cells which then initiates apoptosis - programmed cell death. These 
treatments can not selectively damage cancerous cells and the apoptosis of healthy cells 
is unavoidable.14 There is even the possibility that by damaging healthy DNA secondary 
cancers are created.14 
 
Pancratistatin 5 and 7-deoxypancratisatin 6 (Figure 1) showed very good efficacy against 
the US National Cancer Institute (NCI) human cell lines,8,9,10,11 with pancratistatin being 
the most active anticancer agent of the two.15 Pancratistatin has also shown activity as an 
antiviral6 and antiparasitic7 agent. In fact, 7-deoxypancratistatin and pancratistatin are two 
of only three agents which showed activity in a Japanese encephalitis virus-infected 
mouse model.6
 
Importantly, pancratistatin has also been shown to selectively induce 
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apoptosis in cancerous cells.13 Although the mechanism by which pancratistatin is able to 
induce apoptosis is unknown, the site of action is likely to be the mitochondria of the 
infected cells.13 Interestingly, it is believed that the difference in the mitochondria of 
healthy vs. cancerous cells is one of the main causes for the development of cancers.16 
 
Although medicinally useful Amaryllidaceae alkaloids have been isolated, their potential 
to be used has been hampered due to their low natural abundance. It is thus the onus of 
synthetic chemists to attempt to synthesise these natural products - in an efficient manner 
- so as to allow for extended medical trials and ultimately their prospective use on 
humans.  Pancratistatin has been used in pre-clinical trials as an anticancer agent for two 
decades; this long time frame is attributable to pancratistatin’s low natural abundance and 
lack of viable synthetic routes; an eloquent review of nine of the better total syntheses of 
pancratistatin has been prepared by Kornienko.17 
 
A lot of energy has been spent towards identifying pancratistatin’s pharmacophore and 
mode of medicinal action by the groups of Pettit et al.,18 Faculty et al. 13,19 and Rinner et 
al.20 So far it has been discovered that for a pancratistatin analogue to be effective in 
inducing apoptosis in cancer cells it is necessary that there is: a 2,3,4-triol cyclitol ring 
(Ring C), a full phenanthridone nucleus (Ring A, B and C), trans fused B-C rings and an 
alcohol group or a proton at the A-7 position 7 (Figure 2). It was only through the 
synthesis and testing of a great variety of pancratistatin analogues that these groups were 
able to suggest a minimum pharmacophore; the suggested structural requirements must 
be held in mind if one wants to synthesise a useful anticancer pancratistatin analogue. It 
is thus obvious that there is not very much that can be changed from the original 
pancratistatin molecule for an analogue to be effective.  
NH
X O
OH
OH
C
A B
7
OH
X = OH, H
 
Figure 2 The minimum pharmacophore of pancratistatin 
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1.3 Isolation of pancratistatin 
 
In 1984 Pettit’s group isolated pancratistatin from the bulbs of the Hawaiian plant, 
Pancratium littorale.5 In this study the bulb portion of the plant was extracted with   
dichloromethane-methanol-water. A bioassay using the PS in vivo system showed that a 
compound in the water fraction showed antineoplastic activity. Pancratistatin was then 
extracted from the aqueous phase using n-butanol. Purification was achieved using 
selective solubility properties and gel permeation chromatography on Sephadex-20. 6.5 g 
(0.028%) of pure pancratistatin 10 (Figure 3) was eventually isolated from 45 kg of the 
bulbs used. Pancratistatin was converted to the monomethyl 8 (Figure 3) which was 
subsequently re-crystallized from 95% aqueous ethanol and a crystal structure was 
obtained. In addition the penta-acetate protected pancratistatin 9 (Figure 3) was also 
made. Spectroscopic data of 8, 9 and 10 together with the crystal structure of 8 was used 
to assign the structure of pancratistatin as 10. At this point in time they were not 
confident about assigning the absolute stereochemistry of pancratistatin – although what 
they hypothesised did in fact turn out to be the correct assignment. Pettit’s group also 
showed that the pancratistatin isolated was useful in combating marine P-388 
lymphocytic leukaemia.5  
 
O
O
OMe
NH
HO
OH
OH
OH
O
O
O
OAc
NH
AcO
OAc
OAc
OAc
O
O
O
OH
NH
HO
OH
OH
OH
O
8 9 10
 
Figure 3 The structure of pancratistatin and its derivatives assigned by Pettit 
 
In 1986 Pettit isolated narciclasine 3 and 7-deoxynarciclasine 4 (Figure 1) from the bulbs 
of Pancratium littorale.8 In addition, the isolation of pancratistatin 5 (Figure 1) from the 
bulbs of the plant was slightly improved from 0.028% to 0.039%.  
  
5 
It was also shown that pancratistatin 5 was effective against the P-388 in vitro cell line 
and murine M-5076 ovary sarcoma.8 It was becoming apparent that pancratistatin 5 
(Figure 1) was a potential medicinal champion of the Amaryllidaceae plant alkaloids and 
deserved greater interest from the scientific community. In 1999 Khan et al. published 
methodology of re-extracting pancratistatin from human plasma. The experiments 
conducted provided a greater insight into pancratistatin’s stability in human blood 
plasma. A solid-phase extraction and HPLC assay were used to recover as much as 90% 
of the pancratistatin which had been infused for up to five days in human blood plasma.19 
From a medicinal point of view; the information gathered showed that pancratistatin was 
stable for up to five days, in different concentrations, in human blood plasma. From a 
practical point of view this would mean that re-extracted pancratistatin could be used for 
several trials; this would be very useful in light of its low availability. In 2005, Pettit was 
able to extract pancratistatin (0.041%) from the Texas grasshopper Brachystola magna. 
In addition, they were able to obtain the first crystal structure of pancratistatin.21 The 
medicinal potential of pancratistatin along with the low isolation yields prompted the 
need for a viable synthesis of pancratistatin. 
 
1.4 Synthetic strategies towards pancratistatin – a brief history 
 
A comprehensive set of reviews has been published describing the syntheses of 
Amaryllidaceae anticancer agents; especially with regard to pancratistatin, 7-
deoxypancratistatin, narciclasine and lycoricidine.2,22,23,24,25,26 Recently Kornienko 
published a comparative review of the nine total syntheses of pancratistatin published up 
until 2008.17 
 
In 1989 the first racemic pancratistatin synthesis was achieved by Danishefsky and Lee 
(Scheme 1).27 Their synthesis was an arduous 27 steps and they were able to achieve an 
overall yield of 0.16%. The first key step was the Diels-Alder reaction between the 
butadiene group found on compound 11 and a β-nitrovinyl sulfone to yield the sulfonyl 
nitro compound 12 (Scheme 1). The hexadiene 13 (Scheme 1) was then successfully 
made using tri-n-butyltin hydride to initiate the elimination.  
  
6 
Halolactonisation, using a variety of methods, of the hexadiene 13 (Scheme 1) was 
unsuccessful. They cited the repulsion between the large OTBS and amide group as 
preventing the halolactonisation from occurring. However once the TBS protecting group 
was removed, 14 (Scheme 1) was still resistant to halolactonisation. It was thus decided 
that the nucleophilicity of the carboxamido linkage was not strong enough for the 
reaction to occur. A way to improve the nucleophilicity was via the stannylation of the 
phenolic group.28 This was achieved by reacting 14 with bis(tributyltin)oxide to from the 
stannyl ether 15 (Scheme 1). Iodine dissolved in THF converted the stannyl ether 15 to 
16 and eventually racemic pancratistatin 17 (Scheme 1) over an additional sixteen steps. 
 
TBSO
O
O
O
NEt2
O2N
SO2Ph
TBSO
O
O
O
NEt2
O2N
SO2Ph
OR
O
O
O
NEt2
AIBN, 
Bu3SnH
OH
O
O
O
O
I
OH
O
O
O
NH
OH
OHHO
OH
13 R = TBS
14 R = H11
16pancratistatin 17
12
CHCl3, Heat,
12 h
96% 72%
Bu4NF
80%
OR
O
O
O
O SnH3
(Bu3Sn)2O
I2
67% over
two steps
15
Quantitative
16 steps
 
Scheme 1 Key steps in Danishefsky’s racemic synthesis of pancratistatin.  
 
In 1995 Hudlicky’s group reported the first asymmetric synthesis of pancratistatin 
(Scheme 2).29 The synthesis was an economical 13 steps and had an overall yield of 2%. 
Hudlicky started with the commercially available (1S,2S)-3-bromocyclohexa-3,5-diene-
1,2-diol 18 (Scheme 2) which was prepared from the oxidation of bromo-benzene using 
the bacteria Pseudomonas putida.36 This important starting material already contained the 
cis-diol unit found in pancratistatin.  
 
  
7 
The next challenge was to attach an aryl group to the diol unit which retained the 
stereochemistry required at the C-10b position of pancratistatin. This was achieved by 
making a lithium cyanocuprate of the aryl moiety 21 (Scheme 2) and reacting this with 
the cis-diol unit 20 (Scheme 2). At this point Hudlicky was looking forward to 
completing the phenanthridone core via a transamidation reaction. Unfortunately it was 
found that the position of the tosyl group on the amine relative to the dimethylamide 22 
(Scheme 2) (180°) was not conducive to transamidation to form the cyclized 
phenanthridone core. This unexpected result added a further six steps to the synthesis. 
Subsequently, the tosyl group was replaced by a BOC group to form compound 23 
(Scheme 2). The research group’s luck then got worse as the instalment of the BOC 
group caused problems later as it hindered the α-face of ring C to epoxidation; 
unfortunately it was necessary to remove the BOC group prior to epoxidation and have it 
reinstalled after epoxidation. 
  
A lucky break was finally granted during an attempted opening of the epoxide using a 
catalytic amount of sodium benzoate to yield the required trans-diol. A remarkable set of 
results occurred if the reaction was allowed to proceed over six days: the epoxide was 
opened, both the BOC and benzyl protecting groups were removed and furthermore there 
was ring closure to furnish pancratistatin 32 (Scheme 2). If the reaction was allowed to 
react for a shorter period of time of two days, the reaction yielded the benzylated 
analogue 31 (Scheme 2). 
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OH
OH
Br
O
O
X
TsN
O
O
OTBS
CONMe2
18 19 X = Br
20 X = H
O
O
O
O
NRTs
CONMe2
OTBS
O
O
O
O
NHBOC
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Scheme 2 The first asymmetric synthesis of pancratistatin 
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Later that year Trost and Pulley reported another asymmetric synthesis (Scheme 3).31 
Their synthesis consisted of 20 steps and had an impressive overall yield of 11%. 
Similarly to Hudlicky’s synthesis, Trost started with a cis diol starting material 33 
(Scheme 3). The treatment of 33 with n-butyl lithium, followed by quenching with 
methyl chloroformate yielded the symmetrical dicarbonate 34 (Scheme 3). 
Desymmetrisation of 34 with trimethylsilyl azide was then achieved by using catalytic 
amounts of both π-allylpalladium chloride and ligand 35 to yield the azide 36 (Scheme 
3).  
 
Formation of the C-10b stereochemistry was again problematic; the addition of the aryl 
moiety, using organocuprate chemistry, did not proceed as expected. The researchers 
suggested that the arylcuprate was probably not stable enough for the reaction to occur. 
Trost was eventually able to introduce the necessary stereochemistry by reacting 
Grignard 37 with azide 36, in the presence of cuprous cyanide to yield azide 38 (Scheme 
3).  
 
Another pitfall in their synthesis was in the unexpected non-intramolecular ring closure 
of the isocyanate intermediate formed from compound 39 (Scheme 3). It was suggested 
that acetonide oxygens – a σ-nucleophile - were more nucleophilic than the aryl ring – a 
π-nucleophile - and hence more willing to attack the isocyanate formed. Unfortunately, 
Trost did not either characterize or report the compound that formed as a result of the 
attempted formation of the isocyanate and the expected ring closure of compound 39. The 
problem was circumvented by converting the aryl ring into a stronger σ-nucleophile via 
the introduction of bromine onto the aryl ring 42 (Scheme 3). The late addition of a 
bromine atom to the aryl ring added an additional eight steps and as a result the number 
of total synthetic steps was almost doubled. The rest of the synthesis proceeded smoothly 
towards synthetic pancratistatin 47 (Scheme 3). 
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Scheme 3 Trost’s asymmetric synthesis of pancratistatin 
 
In 1998 Magnus, starting with o-vanillin, reported the synthesis of pancratistatin utilising 
22 steps and an overall yield of 1.5% (Scheme 4).32 Magnus used a β-
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azidobistriisopropylsilyl enol ether functionalization of 48 to 49 (Scheme 4) to install the 
required stereochemistry at the C-10b position.  
The TIPS protecting group “trapped” the enantiomer shown in 95% yield with >85% ee. 
Bischler-Napieralski chemistry was then performed on 50 to give an acetate protected 
phenanthridone skeleton and eventually pancratistatin 51 (Scheme 4). 
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Scheme 4 Key steps in Magnus’s pancratistatin synthesis 
 
A number of additional synthetic approaches towards pancratistatin have been reported. 
These include a synthesis by Rigby’s group who used an aryl enamide photocyclisation 
reaction as his key step to form the trans  B-C ring.  His synthesis was 22 steps with an 
overall yield of 0.35%.33 Pettit’s group used a novel approach whereby they used (+)-
narciclasine as a pre-cursor to (+)-pancratistatin.34 (+)-Narciclasine is readily available 
from some Amaryllidaceae plants and relatively easier to synthesise. From (+)-
naciclasine they were able to synthesise (+)-pancratistatin in 10 steps with a 3.6% total 
yield. More recently Madsen’s group reported the use of two strategies towards the 
synthesis of 7-deoxypancratistatin.35 Both strategies employ the use of carbohydrate 
starting materials, D-ribose and D-xylose, and ring closing metathesis to form ring C. 
Several groups have successfully synthesised pancratistatin however no synthesis to date 
is scaleable. In addition Trost’s synthesis is still the highest yielding. The major 
difficulties in synthesising pancratistatin are the inclusion of the six contiguous 
stereocenters and the stereochemistry required for the trans B-C ring junction. All the 
syntheses share the following commonalities: there are many protecting and deprotecting 
steps and that it is evident that addition reactions play an important role in producing the 
required stereochemistry at site C-10b. It is clear from Trost and Hudlicky’s work that the 
instalment of the stereochemistry at the C-10b site is problematic.  
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The challenges unveiled during the reported syntheses of pancratistatin encouraged our 
investigation into the minimum structural requirements of pancratistatin to be a useful 
medicinal agent. It was hopeful that an efficient synthesis of medicinally potent 
pancratistatin analogues would emerge. In the next section, synthetic work towards the 
synthesis of pancratistatin analogues will be discussed. 
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1.5 Pancratistatin analogues 
In 2004 Kornienko and Nadein published the synthesis of various 1-aryl-1-
deoxyconduritols F analogues 52 (Figure 4);36 possible precursors of pancratistatin and 
7-deoxypancratistatin.  
 
BnO
OBn
OBn
Ar
Ar =
MeO
O
O
O
O
OMe
1-aryl-1-deoxyconduritols F52
 
Figure 4 1-aryl-1-deoxyconduritols F analogues synthesised by Kornienko 
The researchers started by converting D-xylose 53  into the benzyl-protected 54 (Scheme 
5). Diene 55 (Scheme 5) was then made using oxidation and Wittig reactions. A highly 
anti-selective organocuprate addition was then employed to yield 56 (Scheme 5); this 
was a useful way of installing the stereochemistry required at the C-10b site of 
pancratistatin. Reduction, followed by ring closing metathesis (RCM) then yielded the 1-
aryl-1-deoxyconduritol F 58 (Scheme 5). 
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Scheme 5 Kornienko's synthesis of 1-aryl-1-deoxyconduritols F analogues  
Kornienko then went on to publish two more papers describing the use of a 
organocuprate addition reaction in this area: the anti-selective additions to acyclic γ-
alkoxy-α,β-enoates,37 the syn-selective additions to acyclic γ-amino and γ-carbamato-α,β-
enoates.38 As will be discussed later, these results would be of interest as it was our 
intention to apply the same chemistry to a similar acyclic γ-alkoxy-α,β-enoate substituent. 
Their synthesis was practical and efficient in that only 9 steps were required, column 
chromatography was employed only twice and many of the steps were accomplished in 
one pot. 
 
Later in 2006 Kornienko collaborated with a host of individuals to expand on their 
group’s work done in 2004, towards the synthesis of 1-aryl-1-deoxyconduritols F. RCM 
and the useful anti-selective arylcuprate addition were again employed successfully. 
They were able to synthesise 15 B-seco pancratistatin analogues in which ring B of 
pancratistatin was open (Figure  5).39 Unfortunately none of them showed any potential 
as cytotoxic, apoptososis inducing or growth inhibitors against leukaemia and 
adenocarcinoma cell lines. Each analogue had at least four of the stereocenters, including 
the important C-10b stereochemistry, found in pancratistatin.  
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It was suggested that the full phenanthridone skeleton and the complete B-C ring junction 
of pancratistatin was necessary for pancratistatin to exhibit cytotoxity. 
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Figure 5  Kornienko's B-seco pancratistatin analogues  
 
Furthermore work done by McNulty and co-workers towards the synthesis of B,C-seco 
pancratistatin analogues 59 and 60 (Figure 6), also showed that the compounds 
synthesised had little activity in inducing apoptosis in human cancer cells, further 
evidence that the B and C rings need to be complete for a pancratistatin analogue to 
exhibit efficient activity against cancer cells.40  
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Figure 6 McNulty's work towards B,C-seco pancratistatin analogues  
 
In addition to the total synthesis of pancratistatin, Hudlicky along with a number of his 
fellow researchers have invested a considerable amount of energy into the synthesis of 
pancratistatin and 7-deoxypancratistatin analogues. The biological testing of these 
analogues has provided useful insight into pancratistatin’s pharmacophore. Several 
syntheses of these analogues shall be discussed briefly. 
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Scheme 6 Hudlicky’s synthesis of ent-7-deoxypancratistatin 
 
In 2002 Hudlicky and fellow researchers were successful in synthesising ent-7-
deoxypancratistatin 61 (Scheme 6).20 The compound showed activity, with GI50 values of 
2.0 - 3.4 µg.ml-1, against: CNS SF-295, colon KM 20L2, lung NCI-H460, melanoma SK-
MEL-5, ovary OVCAR-3 and renal A498 human cancer cell lines, and the marine 
leukaemia P388 cancer cell line.  
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The activity observed was ten fold less than that of 7-deoxypancratistatin, which 
exhibited GI50 values of 0.22 - 0.47 µg.ml-1 against the same cancer cell lines. The results 
highlighted the importance of the four alcohol groups on ring C to have the correct 
stereochemistry.  
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Scheme 7 Truncated analogues of 7-deoxypancratistatin 
 
In addition to the ent-7-deoxypancratistatin synthesis, the researchers also described the 
synthesis of truncated, B,C-seco, 7-deoxypancratistatin analogues (Scheme 7).20 It was 
found that only the truncated analogue 62 (Scheme 7) showed activity; GI50 values of 5.3 
µg.ml-1 and 8.5 µg.ml-1 were recorded for the pancreas-a BX-PG-3 and lung NCI-H460 
cancer cell lines, respectively. From these results, similarly to the findings of McNulty 
and his fellow researchers,40 it was shown that it was necessary for the B and C ring to be 
complete for 7-deoxypancratistatin to be active.  
 
In 2004 Hudlicky along with Rinner and Pettit published the synthesis of 7-
deoxypancratistatin analogues whereby the oxygen constituents were different on either 
ring A or C.11 It was found that the analogue 63 (Scheme 8), missing the trans diol unit 
on ring C, was only active against murine P388 lymphocytic leukemia; its activity was a 
100 fold less than pancratistatin. Only the analogue having all four alcohol units on ring 
C 64 (Scheme 9) showed activity against both murine P388 lymphocytic leukemia and 
human cancer cell lines.  
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Analogue 64 (Scheme 9) displayed activities about a 100 fold less than pancratistatin 
across the cell lines. Their findings highlighted the importance of having a fully 
oxygenated ring C. In addition, it could be proposed that the alcohol units, especially the 
trans diol unit, of ring C are more important for activity relative to the dioxole unit of 
ring A.    
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Scheme 8  Pancratistatin analogues missing the trans diol unit on ring C which were 
active against murine P388 lymphocytic leukemia 
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Scheme 9  Synthesis of a pancratistatin analogue that was active against both P388 
lymphocytic leukemia and human cancer cell lines 
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Scheme 10 Hudlicky's synthesis of pancratistatin analogues without a dioxole unit on 
ring A 
 
The importance of the dioxole unit on ring A was tested in 2005 by Hudlicky et al.22 
Their work generated some very interesting results. It was found that analogue 65 
(Scheme 10), lacking the dioxole unit and amide moiety, was ten fold less active than 7-
deoxypancratistatin against several cancer cell lines. Analogue 66 (Scheme 10), lacking a 
dioxole unit, also showed similar activities to that of compound 65.  
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Scheme 11 Hudlicky’s work towards a 7-deoxypancratistatin analogue with a modified 
trans diol unit 
 
In 2008 Hudlicky reported the synthesis of a 7-deoxypancratistatin analogue with a 
modified trans diol unit.23  They replaced one of the alcohol groups with an ester and a 
carboxylic acid towards compounds 67 and 68 (Scheme 11) respectively. Their 
biological testing results are pending.  
 
To our knowledge no pancratistatin analogues have been made and biologically tested 
with an open C ring. It would thus be of interest to investigate the synthesis of these 
analogues. 
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1.6 Aims of the project  
 
Our aim was to synthesise C-seco-pancratistatin analogues or to be more precise C-seco-
7-deoxypancratistatin analogues. The synthesis would start with the readily available D(-
)-tartaric acid 69 (Scheme 12). The starting material was chosen as it is readily available, 
relatively inexpensive and contains the two trans alcohol groups as found on ring C of 
pancratistatin. It was our intention to synthesise enantiomerically pure analogues using 
the innate stereochemistry of tartaric acid. Our analogues would have the open cyclitol 
ring C of pancratistatin. Key steps initially envisaged would be the arylcuprate addition 
(vii, Scheme 12) and the isocyanate formation and ring closure (ix, x). As discussed 
previously the highly anti-selective aryl additions were successfully used by Kornienko’s 
group towards the synthesis of pancratistatin analogues.36,39 We would be using this 
methodology in attempting to add the aryl groups to a acyclic γ-alkoxy-α,β-enoate with 
the same R-stereochemistry of the C-10b position of pancratistatin. 
 
 
 
  
24 
OHHO
O
OHHO
O
OHHO
O
OMeMeO
O
OO
O
OMeMeO
O
OO
OHHO
O O
HO OBn
O O
OBn
OMe
O
O O
OBn
OH
O
O
O
O O
OBn
N
C
O
O
O
O O
OBn
NH
O
O
O
O
O
OH
NH
O
HO
OH
OH
OH
HO
OH
OH
NH
O
O
O
i ii
iii
ivv, vi
vii
viii ix
xi
69 70 71
7273
74
75 76 77
7879(+)-pancratistatin 80
x
O O
OBn
OMe
O
O
O
 
Scheme 12 The synthetic strategy we planned to use 
 
In brief, the synthesis would start with the esterfication of D(-)-tartaric acid 69 to afford 
diol 70 (Scheme 12). The diol would then be protected with an acetonide group to yield 
ester 71 (Scheme 12). The reduction of the two ester groups would then lead to the diol 
72 (Scheme 12). The protection of one primary alcohol with a benzyl group would result 
in compound 73 (Scheme 12).  
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The mono benzyl 73 would then undergo a Swern oxidation and Horner-Wadsworth 
reaction to yield the enoate 74 (Scheme 12). Kornienko’s anti-selective organocuprate 
chemistry would then be implemented to install ring A in compound 75 (Scheme 12). 
 
The use of a rhodium catalyst for the anti-addition of the aryl group would also be 
attempted as a synthetic alternative. The functional group inter-conversion of the ester to 
a carboxylic acid 76 (Scheme 12) would then follow suite. The formation of the azide, a 
subsequent Curtius rearrangement to the isocyanate would follow from the carboxylic 
acid to form either the stable isocyanate intermediate 77 or the ring closed product 78 
(Scheme 12). Deprotection of the acetonide and benzyl protecting groups would then 
finally furnish a C-seco pancratistatin analogue 79 (Scheme 12).  
 
The first five steps of the proposed synthesis have been fairly well documented in the 
literature and little concern was placed on these steps. However the aryl additions and 
subsequent attempted ring closure of the isocyanate intermediate would prove to be new 
and exciting territory. 
 
1.7 Aryl additions by metal-mediated 1,4-additions 
 
It was our intention to test Kornienko’s anti-selective arylcuprate additions on our γ-
alkoxy-α,β-enoates. With this in mind, copper-mediated organo additions will be briefly 
reviewed, as well as a rhodium-mediated addition reaction 
 
1.7.1 Organocuprate addition reactions 
 
Organocopper reagents are used in a broad spectrum of applications in organic synthesis; 
they are commonly used to add carbon, hydrogen and heteroatom nucleophiles.41 Organo 
copper reagents have been used for the 1,4-addition of acylic and cyclic nucleophiles to 
acylic α,β-unsaturated enoates.41 With regard to stereoselectivity, it has been proposed 
that the flexability of open ring systems - such as acyclic α,β-unsaturated enoates – do not 
have high selectivities with respect to 1,4-additions using organocopper reagents.41  
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In addition, it has been suggested that selectivities observed during the copper-mediated 
1,4-additions to acylic α,β-unsaturated enoates, is dependant on the group in the γ 
position.41 Fortunately, with respect to the work discussed herein, Kornienko et al. 
successfully employed organocopper reagents to mediate the anti addition of aryl groups 
to γ-alkoxy-α,β-enoates (Scheme 14 and 15).36,39  Kornienko proposed that the anti 
selectivity observed could be predicted using a reductive elimination model (Figure 7).37 
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Scheme 14 Kornienko's use of organocopper chemistry 
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Scheme 15 Kornienko's use of organocopper chemistry 
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Figure 7 Kornienko's reductive elimination model 
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Kornienko and fellow researchers validated the use of the reductive elimination model 
(Figure 8) when they correctly predicted the syn-selective arylcuprate additions to 
acyclic γ-amino- and γ-carbamato-α,β-unsaturated enoates (Scheme 16 and 17).38  
 
Ar =
MeO F
Ar2CuMgBr,
TMSCl, THF,
-78 oC to rt
58%, >20:1 50%, >20:1 55%, >20:1
O
O
MeO
MeO
O
O
OMe
ButPh2SiO
NBn2
O
OMe ButPh2SiO
NBn2
Ar O
OMe
Cl
58%, >20:1 49%, >20:1 52%, >20:1 0%
 
Scheme 16 Kornienko's syn-selective arylcuprate additions  
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Scheme 17  Kornienko's syn-selective arylcuprate additions 
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Figure 8 Reductive elimination model used to predict the outcome of the syn-selective 
arylcuprate additions 
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1.7.2 Rhodium catalyzed reaction 
 
In 1997, Miyaura reported the rhodium catalysed conjugate addition of both aryl and 
alkenyl boronic acids to acyclic and cyclic enones.42 In this work 3 mol % Rh(acac)(CO)2 
and 1,4-bis-(diphenylphosphino)butane (dppb) was used to catalyse the addition of a 
variety of aryl boronic acids to numerous enones at 50°C in aqueous solvent. A year later, 
Hayashi and Miyaura published work concerning the rhodium catalysed asymmetric 1,4-
addition of aryl boronic acids.43 In their paper they achieved high enantioselectivity and 
impressive yields. Miyaura’s investigation into using a rhodium catalyst for the addition 
of boronic acids to enones prompted other groups to investigate various other rhodium 
catalysts and reaction conditions for the addition of boronic acids to: α,β-unsaturated 
ketones43, α,β-unsaturated esters44 and α,β-unsaturated amides.45  
 
More importantly for our work, Segura and Csaky recently published a paper describing 
the use of a catalytic amount of [(cod)RhCl]2 for the anti-addition of aryl- and 
alkenylboronic acids to acyclic γ,δ-oxy-α,β-unsaturated enoates.46 The chemistry 
described in this paper is very useful as: the rhodium catalyst and boronic acids are stable 
when exposed to oxygen and water, the reactions can be done in aqueous solvents at low 
temperatures and high enantioselectivity and conversions are possible. 
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Chapter 2: Results and discussion 
2.1 Preparation of open chain pancratistatin analogues 
2.1.1 The ‘Natural’ trial synthesis 
Similarly to Hudlicky and Trost’s pancratistatin syntheses,28,30 it was our intention to use 
the inherent trans diol stereochemistry - the 2S,3S stereocenters of D(-)-tartaric acid 69 
(Figure 9) - towards the synthesis of enantiomerically pure, open chain pancratistatin 
analogues. L(+)-tartaric acid 81 (Figure 9) was initially used as the starting material for a 
‘trial’ synthesis. L(+)-tartaric acid is less expensive than D(-)-tartaric acid and was 
readily available in our laboratory. L(+)-tartaric acid or ‘Natural’ tartaric acid is found 
commonly in grapes and its potassium hydrogen tartrate salt sometimes precipitates out 
of wines. In addition it was anticipated that chemistry used on the two tartaric 
enantiomers would yield similar results.  
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Figure 9 The starting materials we intended to use towards the synthesis of  
pancratistatin analogues 
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2.1.1.1 Synthesis of ester 82 
The synthesis started with the esterification of L(+)-tartaric acid 81 (Scheme 18). L(+)-
tartaric acid 81 was thus dissolved in methanol and thionyl chloride was cautiously added 
drop-wise over one hour at 0°C. 24 The reaction mixture was then heated at reflux for 
eighteen hours. No purification was necessary, removal of the solvent in vacuo yielded 
ester 82 (Scheme 18) as a light yellow oil with a respectable 86% conversion.  
HO2C
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CO2H
HO
L(+)-tartaric acid
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MeOH, SOCl2,
0oC then reflux, 18h
86%
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CO2Me
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Scheme 18 
The 1H NMR spectrum of 82 (Scheme 18) indicated a singlet at 3.9 ppm integrating for 6 
hydrogen atoms, this shift was attributable to the presence of the two ester methyl groups. 
The chemical shift compared favourably with the literature which reported the same 
chemical shift at 3.8 ppm.47 In addition, the trans-diol gave rise to a broad signal 
integrating for two protons at 3.5 ppm on the 1H NMR of 82. A signal at 170.0 ppm on 
the 13C NMR spectrum of 82 was characteristic of the two carbonyl groups. The literature 
reported the carbonyl groups giving rise to a signal at 173.0 ppm.47 Two signals at 51.1 
ppm (lit.47 52.7 ppm) on the 13C NMR spectrum of 82 confirmed the presence of the two 
methoxy functionalities.  
2.1.1.2 Protection of the diol unit with an acetonide protecting group 
The next step involved the protection of diol 82 with an acetonide protecting group 
towards 83 (Scheme 19). Diol 82 was dissolved in DMF and then heated at reflux for 
eighteen hours in the presence of 2,2-dimethoxy propane and a catalytic amount of p-
toluene sulphonic acid monohydrate (PTSA).25 The solvent was removed in vacuo and 
the resulting red residue was washed with sodium hydrogen carbonate and extracted with 
chloroform.  
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The removal of the solvent in vacuo and subsequent distillation (bp 130°C at 6 mmHg vs. 
lit.48 bp 82 – 90 °C) yielded the acetonide-protected product 83 (Scheme 19) , as a dark 
orange oil, with a reasonable 60% yield.  
MeO2C
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CO2Me
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2,2-dimethoxy propane,
PTSA, DMF, reflux, 18h
MeO2C
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CO2Me
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Scheme 19 
Inspection of the 1H NMR spectrum of 83 (Scheme 19) indicated: the newly added 
acetonide functionality giving rise to a signal integrating for 6 protons at 1.5 ppm (lit.48 
1.5 ppm), the absence of the diol signal - evident as a broad peak at 3.51 ppm in the 1H 
NMR spectrum of 82 (Scheme 19). In addition, there was a singlet at 3.83 ppm in 
compound 83’s 1H NMR spectrum which could be assigned to the two methoxy groups. 
The literature reported the same signal at 3.80 ppm.48 The 13C NMR spectrum of 83 
included: a carbonyl chemical shift at 170.4 ppm (lit.48 169.9 ppm), a chemical shift at 
114.2 ppm (lit.48 113.7 ppm) which was assigned to the CH group of the acetonide and 
the two methyl groups of the acetonide protecting-group gave rise to a signal at 26.6 ppm 
(lit.48 26.2 ppm).      
2.1.1.3 Reduction of diester 83 towards diol 84 
OO
84
MeO2C
O
CO2Me
O
83
HO OH
LiAlH4, Et2O,
0oC then reflux, 18h
68%
 
Scheme 20 
The third step in this synthetic sequence was the reduction of the ester groups to their 
corresponding primary alcohols.  
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The ubiquitous reducing agent lithium aluminium hydride (LAH),26 was successfully 
employed to reduce diester 83 to the diol 84 (Scheme 20). To this end, LAH in diethyl 
ether was vigorously heated at reflux for 30 min. and then cooled to room temperature. 
Ester 83 was dissolved in diethyl ether and added drop-wise to the LAH/Et2O mixture 
cooled to 0°C, over one hour. The reaction mixture was then heated at reflux. The 
standard acid work-up was not employed as we were concerned that under acidic 
conditions the acetonide-protecting group may be cleaved. Instead a somewhat messy 
base work-up was employed. It is possible that some of the diol product was lost during 
the work-up stage as extraction of the organic products proved to be difficult. Purification 
was achieved by way of a silica gel plug and a 68% yield of the desired compound, an 
opaque semi-solid, was achieved. It was later found, in attempts to remove the acetonide, 
that the acetonide-protecting group was resilient to acids; ethereal hydrochloric acid was 
unable to remove the acetonide. It is thus suggested that the acid work-up be tested for 
future reactions. The following evidence for the formation of compound 84 was seen in 
its 1H NMR spectrum. A broad signal integrating for 2 H’s at 3.01 ppm on the 1H 
spectrum of 84 indicated the presence of the two alcohol groups. The obvious absence of 
the esters methyl groups, a singlet at 3.86 ppm integrating for six H’s on the 1H NMR 
spectrum of 83, provided further evidence for the formation of diol 84. A multiplet 
signal, integrating for two protons, at 3.97 ppm was assigned to the two CH groups beta 
to the two alcohol groups. Furthermore, the presence of the two CH2 groups alpha to the 
alcohol groups gave rise to a multiplet signal, integrating for four protons, at 3.75 ppm on 
the 1H NMR spectrum of 84. Examination of the literature validated the 1H NMR 
spectrum of compound 84 further by the inclusion of the following signals: the two CH 
groups beta to the alcohol groups gave rise to a multiplet at 3.94 ppm, and the CH2 
groups alpha to the two alcohol groups gave rise to a multiplet signal at 3.71 ppm.48 The 
absence of the carbonyl peaks, seen at 170.4 ppm on the 13C NMR spectrum of ester 83, 
provided further evidence for the successful reduction of ester 83 towards diol 84.  
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2.1.1.4 Mono protection of diol 84 
Diol 84 was then converted into the mono-benzyl protected alcohol 85 (Scheme 21).49 
Initially, sodium salt 86 (Scheme 21) was prepared by treating diol 84 with sodium 
hydride in the presence of THF at 0°C. It was anticipated that the addition of 1.2 
equivalents of sodium hydride would result in the kinetically favourable mono-sodium 
salt 86 (Scheme 22). The strongly nucleophillic oxygen of the sodium salt would then be 
expected to readily attack the electrophillic methylene group α to the bromine atom to 
yield the mono-protected product 85 (Scheme 22).   
OO
85
OO
84
BnO OH
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Benzyl bromide, reflux, 17h
66%OHHO
OO
OH+Na-O
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       86
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Scheme 21 
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Scheme 22 
Upon addition of the sodium hydride to diol 84 (Scheme 21), the formation of a salt was 
indicated by the evolution of a cream coloured precipitate. Benzyl bromide was then 
added and the reaction mixture heated at reflux to complete the mono protection 
sequence. Column chromatography then yielded the mono-protected alcohol 85 (Scheme 
21), a light yellow oil, with a moderate yield of 66%.  
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The 1H NMR spectrum of compound 85 (Scheme 21) provided the following evidence: a 
signal integrating for five protons at 7.32 ppm which could be assigned to the benzyl 
group and a singlet integrating for two protons at 4.58 ppm which were assigned to the 
benzyl’s methylene group.  
A relatively small quantity of the bi-protected product 87 (Scheme 21) was also retrieved 
off the column, indicating that either the kinetically unfavourable bi-sodium salt had 
formed or that some of the starting material had not been converted into a mono-sodium 
salt and was thus bi-protected. The formation of the unexpected salt illustrates the 
inherent bellicosity of certain organic molecules.  
2.1.1.5 Attempted Swern and Wittig reaction towards α,β-enoate 89 
The attempted Swern oxidation and sequential Wittig reaction50 of 85 towards enoate 89 
(Scheme 23) did not proceed with any confidence; attempts would yield the starting 
material 85. It was then decided to investigate other possible in-situ oxidation\addition 
reactions which would serve our purposes. 
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Scheme 23 
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2.1.2 Tandem oxidation process (TOP) 
2.1.2.1 The used of manganese dioxide and a stable Wittig reagent – Taylor’s method 
In the 1990’s Taylor successfully used activated manganese dioxide and stabilized Wittig 
(ylide) reagents in a variety of tandem oxidation processes (TOP).51-54 Since this 
discovery manganese dioxide has been employed successfully in TOPs. These include: 
the use of non- and semi-stabilized ylides to yield α,β-unsaturated aldehydes and β-
unsaturated di-bromo compounds,55,56 the use of sulphur ylides to yield cyclopropane 
products57 and the conversion of  amines and O-alkyl hydroxylamines towards imines 
and oximes respectively.58,59  
Historically, activated manganese dioxide was used for the oxidation of activated 
(benzylic\allylic\propargylic) primary alcohols to afford aldehydes. It was believed that 
activated manganese dioxide was unable to oxidize un-activated primary alcohols.60 
Taylor used the oxidizing ability of activated manganese dioxide in tandem or in-situ 
with a stabilized Wittig reagent to trap the aldehyde formed. In this way the researchers 
were able to perform a TOP on ‘semi’ activated and completely un-activated primary 
alcohols.61 The non-toxicity of activated manganese dioxide, ease of reaction and work-
up – a simple filtration - made this chemistry desirable for our synthesis. A representative 
example pertinent to our work is the TOP of the un-activated alcohol 90 towards enoate 
91 (Scheme 24).62  
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C11H23
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CO2Et90 91
 
Scheme 24 
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Using Taylor’s methodology it was possible to isolate enoate 89 (Scheme 25) as a bright 
yellow oil, with a 40% yield and E:Z ratio of 3.5:1.61 The E:Z ratio was determined by 
comparing the E isomer’s 1H NMR spectrum’s signal – the proton alpha to the ester 
group -  height to that of the Z isomer’s 1H NMR spectrum signal height – again, the 
proton alpha to the ester group. Examination of 89’s (Scheme 25) 1H NMR spectrum 
showed that: the spectrum did not contain a signal for an alcohol group - a broad singlet 
integrating for one proton at 2.42 ppm on the 1H NMR spectrum of 85, and the methyl 
group of the newly added ester was accountable for a singlet at 3.67 ppm (lit.63 3.75 ppm) 
integrating for three protons. In addition two double doublets, each integrating for one 
proton, at 6.87 ppm and 6.00 ppm, indicated the presence of the alkene functionality. The 
signals assigned to the two alkene protons compared favourably with the literature values 
of 6.92 ppm and 6.11 ppm for the respective protons.63 In addition, the coupling constants 
that were calculated for compound 89’s alkene proton alpha to the ester group and beta 
proton were J = 15.7, 5.3 Hz and J = 15.7, 0.7 Hz respectively. These values 
corresponded relatively well with the literature values of J = 15.5, 5.4 Hz and J = 15.5, 
1.6 Hz for the equivalent protons.63 
The yield over two steps was promising but the E:Z ratio was not high enough for our 
synthesis. It should be noted that the activated manganese dioxide that was used was not 
freshly prepared and was probably in need of purification.  
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2.1.2.2 Pyridinium chlorochromate and the stable Wittig reagent – from Corey to Shet 
We next turned to the use of pyridinium chlorochromate (PCC) as an oxidizing agent. In 
1975 Corey reported the use of PCC for an oxidizing agent of primary and secondary 
alcohols towards their corresponding carbonyls.64 The use of PCC in a TOP with a stable 
Wittig reagent was recently documented by Bressette and Glover.65 Although the process 
was not truly in-situ, it still took place sequentially in ‘one pot’.  
In the same year, Shet et al. reported the first proper in-situ use of PCC and a stable 
Wittig reagent for the conversion of a number of activated and un-activated primary 
alcohols into their aldehydes with a contiguous E:Z ratio of 9:1 for all of their TOP 
reactions.66  
The in-situ Shet-type TOP was applied in our case.66 Alcohol 85 (Scheme 26) was thus 
treated with PCC buffered with sodium acetate at room temperature and stirred for ten 
minutes. Subsequently the stable Wittig reagent, methyl 
(triphenylphosphoranylidene)acetate, was added and the reaction mixture was stirred at 
room temperature for twenty hours.  
The reaction mixture was then filtered through celite and the enoate 89 (Scheme 26) 
isolated by way of column chromatography. A yield of 8.2% was truly disappointing as it 
was a severe payoff against an improved E:Z ratio of 8:1.  
Analysis of the 1H NMR spectrum of 89 (Scheme 26) showed: the removal of the alcohol 
group by the absence of the alcohol signal. In addition, two new signals, double doublets 
at 6.87 ppm (lit.63 6.92 ppm) and 6.00 ppm (lit.63 6.11), indicated the presence of the 
alkene functionality. The methyl group of the ester was also accounted for by a singlet at 
3.67 ppm (lit.63 3.75) integrating for three protons. As mentioned, there was a much 
improved E:Z ratio. Interestingly, the ratio is very close to that reported by Shet et al. 
(E:Z = 9:1) and it could be proposed that this is the E:Z ratio limit of this type of TOP.   
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Scheme 26 
2.1.3 The successful synthesis of α,β-unsaturated enoate 74 
The disappointing E:Z ratios observed for the MnO2 and PCC TOPs redirected attentions 
towards the use of the Swern-Wittig reaction. In addition, the arrival of fresh oxalyl 
chloride and DMSO allowed for the testing of the sequential Swern-Wittig reaction.50 At 
this point, the ‘trial’ synthesis ended and efforts were directed into using the ‘unnatural’ 
D(-)-tartaric acid 69 (Scheme 27). D(-)-tartaric acid contains the correct stereochemical 
elements required for the synthesis of a pancratistatin analogue; namely the correct 
stereochemistry for the trans diol unit found on ring C of pancratistatin. Now starting 
with the ‘unnatural’ tartaric acid 69; we repeated all of the steps that have previously 
been described - barring the activated manganese and PCC TOPs. This has been 
illustrated in Scheme 27 and will be briefly discussed. Diester 70 (Scheme 27) was 
produced and isolated, with an 87 % yield, in exactly the same way as the ‘natural’ 
diester 70. Examination of the 1H and 13C NMR spectrum of 70 included the following 
signals: a singlet, integrating for six protons, at 3.59 ppm (lit.67  3.87 ppm) which was 
assigned to the two newly added methyl groups, and a carbonyl signal at 172.3 ppm.  
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Scheme 27 
The acetonide protection of diester 70 proceeded smoothly to yield compound 71 
(Scheme 27) with a slightly improved yield of 65 % relative to the ‘natural’ acetonide 
protection yield of 60 % towards compound 83 (Scheme 19). The 1H NMR spectrum 
signals of compound 71 corrsponded well with literature values. The signal at 4.81 ppm 
(lit.67 4.80 ppm) was assigned to the two protons alpha to their adjacent ester groups.  
  
40 
A singlet integrating for six protons at 1.49 ppm (lit.67 1.50 ppm) was attributable to the 
presence of the two newly added methyl groups of the acetonide-protecting group. A 
signal in the 13C NMR spectrum of compound 71 (Scheme 27) occurring at 114.2 ppm 
was a clear indication of the presence of the O-CH-O bridge of the acetonide-protecting 
group. The reduction of the ester groups towards their corresponding primary alcohols to 
produce diol 72 (Scheme 27) with a 70 % yield, proceeded more smoothly than the 
reduction of 83 towards diol 84 (Scheme 20). The major reason being the experience 
gained from extracting diol from the work up mixture in the manufacture of diol 84. The 
1H NMR spectrum of 72 included the following signals: a multiplet in the range of 3.67 – 
3.78 (lit.67 3.69 – 3.82), integrating for four protons which was assigned to the two CH2 
groups alpha to the primary alcohol groups, and a triplet, J = 5.55 Hz, signal at 3.09 ppm  
which integrated for two protons – this signal was assigned to the two primary alcohol 
protons. The shifts recorded for compound 72 were in agreement with the literature and 
the synthesis proceeded to the last of the known chemistry steps – the mono-protection of 
diol 72 towards compound 73 (Scheme 27). The chemistry used was again the same as 
that applied in the synthesis of mono-protected compound 85 (Scheme 22) . The 
formation of compound 73 was validated by the 1H and 13C NMR spectra. The 1H NMR 
spectrum had a multiplet integrating for five protons in the range of 7.26 – 7.34 ppm, this 
signal was a clear indication of the presence of the five aromatic protons belonging to the 
benzyl-protecting group. A review of the literature showed this same shift to occur in the 
range of 7.31 – 7.40 ppm.68 A singlet at 4.58 ppm (lit.68 4.60 ppm) was assigned to the 
CH2 group bridging the alcohol and aryl group. The 1H NMR spectrum of 73 also showed 
the existence of an AB system; signals at 3.77 ppm and 3.72 ppm, each integrating for a 
single proton and with J = 11.5, 4.2 Hz and J = 7.5 Hz respectively, could be assigned to 
the CH2 group alpha to the newly protected alcohol. The coupling constants recorded did 
not agree well with literature values of J = 4.4, 2.2 Hz and J = 5.6 Hz.68 However the shift 
positions did correspond fairly well with literature values of 3.74 ppm and 3.64 ppm.68 
Our synthesis proceeded on towards the Swern-Wittig reaction. The Swern reagent was 
prepared by stirring oxalyl chloride with DMSO for ten minutes at -60°C.  
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Alcohol 69 (Scheme 27) was then added carefully and the reaction mixture stirred for 
fifteen minutes at -60°C before triethylamine was added. The reaction mixture was then 
warmed to room temperature and the solvent was hastily removed in-vacuo. The 
characteristic stench of dimethyl sulphide was evident to many unfortunate colleagues - a 
great victory! The yellow coloured aldehyde was promptly added to the prepared Wittig 
reagent at -20°C and stirred for one hour. The Wittig reagent was synthesised by treating 
trimethyl phosphonoacetate with sodium hydride for one hour at -20°C. The desired 
enoate 74 (Scheme  27) was obtained after purification by column chromatography. A 
reasonable yield of 42%, over two steps, and 1H NMR spectrum analysis of compound 74 
indicated that an E:Z = 25:1 was achieved.  This was in contrast with the low E:Z ratios 
observed for the activated manganese and PCC TOPs.  
The elimination of the alcohol group was shown by the absence of the alcohol signal. In 
addition, there were two double of doublets in the 1H NMR spectrum of compound 74 
(Scheme 27) at 6.91 and 6.11 ppm, each integrating for one proton; these signals 
corresponded to the presence of the alkene functionality. Coupling constants of J = 15.7, 
5.6 Hz and J = 15.7, 1.4 Hz were recorded for the two alkene protons. The methyl group 
of the ester was accountable for a singlet integrating for three protons at 3.73 ppm. A 
chemical shift at 166.29 ppm on the 13C spectrum of 74 was assigned to the carbonyl 
group of the ester. 
All of the compounds made up until this point have been previously synthesised by other 
research groups. We now left the known behind and set our vision towards the synthesis 
of a series of novel compounds. So far, in six steps we had achieved a 13.3% conversion 
of D(-)-tartaric acid towards enoate 74 (Scheme 27). 
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2.1.4 The use of arylcuprates for the installation of aryl groups 
As mentioned in the introduction, Kornienko used highly anti-selective organocuprate 
conjugate additions to install the stereochemistry equivalent to the C-10b position of 
pancratistatin.36,38,39 
Before testing his approach on our enoate 74 (Scheme 27) we cautiously decided to do a 
set of trial organocuprate additions on a model substrate, the system α,β-unsaturated 
methyl cinnamate 92 (Scheme 28). The general procedure used was as follows. The aryl 
Grignard reagent was made by combining the appropriate aryl bromide compound with 
magnesium turnings, in THF, at room temperature. The organocopper reagent was then 
completed by way of the cannulation of the Grignard reagent into a suspension of copper 
(I) iodide in THF at -78°C. The reaction mixture was subsequently stirred for one hour. 
Trimethylsilyl chloride (TMSCl) and the enoate methyl cinnamate 92 were then 
cannulated into the organocopper reagent. The reaction was allowed to warm to room 
temperature and stirred for eighteen hours.38 Scheme 28 shows the arylbromide utilised in 
the study and the yields obtained. 
CO2Me
Ar2CuMgBr, TMSCl,
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OMe
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Although the yields were nothing to boast about, the trial reactions served as good 
practice for the substrate required in this synthesis. It must be noted that the 
organocuprate conjugate addition reactions were relatively laborious; work ups were 
difficult and purification always involved the separation of several compounds with 
similar polarity including large amounts of biaryl compounds which formed due to the 
large excess of cuprate reagent; 5 mol equivalents of cuprate reagent were used. 
The 1H NMR spectrum of compound 93 (Scheme 28) included the following signals: a 
multiplet integrating for ten protons was attributable to the aromatic protons, a doublet 
integrating for two protons at 3.06 ppm was assigned to the CH2 group alpha to the ester. 
From the 1H NMR spectrum of compound 94 (Scheme 28) we could assign: a multiplet 
integrating for nine protons at 7.21 ppm to the aromatic protons, a triplet integrating for 
one proton at 4.50 ppm to the proton beta to the ester, a singlet integrating for three 
protons at 3.75 ppm for the methoxy group. The difficulty experienced in purifying the 
conjugate addition products peaked when we were unable to purify compound 95 
(Scheme 28), despite several attempts to obtain a reasonable 1H NMR spectrum. It was 
thus necessary to convert ester 95 into its carboxylic acid 96 (Scheme 29)- using a 5% 
aqueous potassium hydroxide solution. The 1H NMR spectrum of 96 included the 
following signals: a broad singlet integrating for one proton at 9.54 ppm due to the 
carboxylic acid functionality and two singlets integrating for three protons each at 3.81 
and 3.79 ppm which were assigned to the two methoxy groups. The functional group 
conversion of the ester to the carboxylic acid also served as practice for a similar future 
transformation. 
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2.1.5 Testing Kornienko’s cuprate chemistry on α,β-enoate 74 
Considering the results of the organocuprate additions performed on methyl cinnamate 92 
(Scheme 28); the search was on for an alternative reaction which would afford the same 
conjugate addition with high stereoselectivity and good conversions. However, in the 
meanwhile the organocuprate chemistry was used on the α,β-unsaturated enoate 74 
(Scheme 30). The methodology used was identical to that described for the 
organocuprate additions performed on methyl cinnamate 92. It was possible to isolate the 
addition product 97 (Scheme 30) with a respectable yield of 86%. The 1H NMR spectrum 
of compound 97 had a chemical shift integrating for ten protons between 7.13 ppm and 
7.28 ppm; this indicated the presence of the newly added phenyl group. The two double 
of doublets at 6.91 and 6.11 ppm – accountable for the alkene protons in enoate 74 – 
were not present in the 1H NMR spectrum of product 97
.
 A multiplet integrating for two 
protons at 2.81 ppm on the 1H NMR spectrum of addition compound 97 confirmed the 
presence of the new CH2 group α to the ester. At this point no attempts were made to 
validate the stereochemistry of the addition product. The 1NMR spectrum of compound 
97 did indicate that there was a very large diastereomeric excess in the range of 200:1. 
Considering Kornienko’s findings,37 it could be proposed that it was very probable that 
the anti-addition did in fact occur.  
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Scheme 30 
As mentioned previously, the cuprate addition reaction proved to be tedious: the work up 
was difficult and laborious and the reaction requires several processes to take place at low 
temperatures. Unlike the trial organocuprate reactions, the purification was not as 
problematic as only two compounds had to be resolved via column chromatography.  
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This is where all affairs with organocuprate chemistry ended. It has been shown – 
contrary to previous findings – that α,β-unsaturated enolates that contain a γ-oxygen are 
not amicable substrates towards conjugate additions; this is because the γ-oxygen – being 
an electron donor – makes the β-position of the enoate less electrophillic.69  
A search of the literature provided a more a far more attractive, affable and expensive 
prospect for the 1,4-addition to the γ-alkoxy-α,β-enoate used in this synthesis. Her name 
was rhodium and dressed in the appropriate ligands she was elegant and useful. 
2.1.6 Rhodium (I) – a lascivious catalyst 
The use of Rh(I) catalysts for the anti-addition of aryl boronic acids to acyclic             
α,β-unsaturated enoates was discussed in the introduction. In 2007, Csaky and Segura 
reported the use of a Rh(I) catalyst for the addition of a number of aryl- and 
alkenylboronic acids to γ,δ-oxygen-substituted-αβ-unsaturated acyclic enoates.46 They 
found that the conjugate additions proceeded with high anti-selectivity and impressive 
yields. They also reported that the high stereoselectivities were because the additions 
were substrate controlled; the δ-oxygen, if protected, yielded highly anti-selective 
products. A representative example of their work is shown in Scheme 31.  
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Scheme 31 
Csaky and Segura proposed that the rate determining step of the catalytic cycle, and the 
step responsible for the diastereosectivity, to be the formation of the oxo-π-allyl-RhI 
intermediate. In addition, they proposed two transition state models as shown in Figure 
10. In building their two models, steric hindrance was minimized by the lack of co-
ordination between the rhodium metal and the OR1 and OR2 groups – in our case this 
would be the acetonide protected oxygens.  
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They proposed that the diastereoselection was occurring at either transition state model I 
or II (Figure 10) and calculated that transition state model I was energetically more 
favourable than transition state II. Their reasoning being, in model I the nucleophile 
would enter anti-periplanar to the lowest σ*-lying orbital of the γ-C-OR1 bond, while in 
model II the nucleophile would enter anti-periplanar to the γ-C-OR2 bond. Model I can 
also clearly be used to rationalize the anti-selective products.46 
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Figure 10 Segura's transition state models 
This was great news for us as we were attempting additions on a similar compound and 
also required an anti-selective addition. 
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Scheme 32 
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The rhodium catalysed 1,4-additions were relatively - compared to the organocuprate 
reactions - easy to perform. Addition compound 100 (Scheme 32) was prepared in the 
following manner: a dry mixture of phenylboronic acid and the Rh(I) catalyst was 
initially made, enoate 74 (Scheme 32) was dissolved in 1,4-dioxane:H2O (10:1) and was 
then added to the dry mixture and lastly triethylamine was added. The reaction mixture 
was stirred at room temperature for 24 hours under an argon atmosphere. The reaction 
mixture was subsequently dried onto silica gel and compound 100 isolated by means of 
column chromatography. A respectable yield of 95% was achieved and 1H and 13C NMR 
analysis showed no evidence of the existence of another diastereomer. At this point it was 
not possible to determine if the reaction proceeded with anti- or conversely with syn-
selctivity. The subsequent formation and x-ray structure determination of a carboxylic 
acid derivative 101 (Figure 11) of addition product 100 proved that the Rh(I) catalysed 
reaction proceeded with anti-selectivity – this will be discussed in the next section. The 
1H NMR spectrum of addition product 100 had a multiplet in the range of 7.15 – 7.29 
ppm integrating for 10 protons; these protons could be assigned to both the benzyl-
protecting group and the newly added aryl group. The signals at 6.91 and 6.11 ppm on 
the 1H NMR spectrum of starting material 74, which were assigned to the alkene protons 
of enoate, were no longer present in the 1H NMR spectrum of compound 100. Instead 
there was: a multiplet signal at 2.80 ppm integrating for one proton - the single proton at 
the CH-aryl junction, and a double of doublets signal at 2.68 ppm integrating for two 
protons – the CH2 group α to the ester. The addition compound 75 (Scheme 32) was 
made in exactly the same way as compound 100; the obvious difference being the use of 
3,4-(methylene dioxy)-phenyl boronic acid as the source of the aryl group to be added to 
enoate 74 towards compound 75 and slightly less Rh(I) catalyst was used. The 1H NMR 
spectrum of 75 did not contain the alkene signals found in the 1H NMR spectrum of 
compound 74. The CH2 functionality of the dioxole group gave rise to a double of 
doublets at 5.89 ppm on the 1H NMR spectrum of 75. In addition, there was a multiplet 
integrating for three protons, in the range of 6.60 – 6.68 ppm, this chemical shift could 
assigned to the newly added aryl group’s protons. The 1H and 13C NMR spectra of 
compound 75 did not indicate the presence of a diastereomer.  
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The production of 75 and 100 (95%, 90%) using 4.2 and 2.7 mol % Rh(I) catalyst 
respectively, the appropriate aryl boronic acid and triethylammine proceeded efficiently, 
with high stereoselectivity and conversion. This was in agreement with the results of 
Csaky and Segura.46  
2.1.7 Functional group inter-conversion – hydrolysis of the ester functionalities  
The next important step in the synthesis necessitated the hydrolysis of the ester 
functionalities. Fortunately the inter-conversion had been employed successfully on 
compound 95 towards acid 96 (Scheme 29).70 Ester 100 (Scheme 32) was dissolved in 
methanol before a 5% aqueous potassium hydroxide solution was added.70 The reaction 
mixture was stirred overnight at room temperature under a room atmosphere. A base-acid 
work up – starting with sodium hydrogen carbonate and finally 10% hydrochloric acid - 
was employed to retrieve and purify the desired acid 101 (Scheme 33) with a decent 
yield of 80%. The 1H NMR spectrum of carboxylic acid 101 no longer contained a shift - 
a singlet integrating for three protons at 3.52 ppm on the 1H NMR spectrum of compound 
100 – which indicated the presence of the ester’s CH3 group present on ester 100. In 
addition, there was a broad peak at 9.00 ppm on the 1H NMR spectrum of acid 101; this 
signal corresponded to the newly formed alcohol functionality of the carboxylic acid. 
Ester 75 (Scheme 32) was also stirred in a mixture of methanol and 5% aqueous 
potassium hydroxide to yield carboxylic acid 76 (Scheme 33).70 Acid 76 was, like 
compound 101, retrieved and purified - with an excellent 95% yield - through a base-acid 
work up; similarly using sodium hydrogen carbonate and 10% hydrochloric acid. The 1H 
NMR spectrum of compound 76 did not contain an ester chemical shift as found on the 
1H NMR of compound 75. A broad signal, assigned to the carboxylic acid’s alcohol 
group, was evident on the 1H NMR spectrum of acid 76 at 9.00 ppm. 
In subsequent attempts, the work up was simplified; the methanol was removed in vacuo 
and the resulting residue was washed with water and extracted with ethyl acetate to yield 
carboxylic acids 76 and 101 (Scheme 33) with reasonable purity. 
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2.1.8 Confirmation of the anti-selectivity for the Rh(I) catalysed additions 
Re-crystallization of  101 (Scheme 33) in hexane allowed for a crystal structure to be 
obtained. Looking at the CH-protons coloured in blue and green (Figure 11), it can be 
clearly seen that the Rh(I) catalysed 1,4-additions had proceeded with anti-selectivity. 
The rhodium catalysed reaction had shown itself to be a useful alternative to the 
organocuprate chemistry previously used. In addition, the Rh(I) catalysed 1,4-addition 
proved to be a novel method of installing aromatic groups with the stereochemistry 
required for site C-10b of pancratistatin. 
 
Figure 11  Crystal structure obtained for compund 101 
The anti-selectivity observed complemented the findings of Csaky and Segura.46 Csaky 
and Segura’s transition state model I (Figure 12) could also be used to predict the anti-
selectivity observed for the Rh(I) catalysed 1,4-additions to σ,γ-alkoxy α,β-unsaturated 
enoate 102 (Figure 12).  
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Looking at transition state model I and II (Figure 12) it could also be proposed that - due 
to the steric hindrance resulting from the interaction of the benzyl protecting group and 
ester functionality - transition state model II is energetically less favourable than 
transition state model I. Model I can again be used in this case to rationalize the anti-
selective products.46 
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Figure 12 Segura's transition state models 
2.1.9 Completing the open chain through a ring 
With the two carboxylic acids 76 and 101 (Scheme 33) in hand the completion of ring B 
of pancratistatin could be attempted. The plan envisaged was, using diphenyl phosphoryl 
azide (DPPA) as the azide transfer agent, to initially convert the carboxylic acids into 
their corresponding azides. Finally, it was hoped, that subsequent heating would then 
promote a Curtius rearrangement to afford the isocyanate intermediates 77 and 106 
(Scheme 34). Scheme 34 illustrates the possible mechanisms by which the azide is 
formed and the subsequent Curtius rearrangement.  
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Scheme 34 Curtius rearrangements 
The electron pair in the phosphorous-nitrogen bond of DPPA 103 (Scheme 34) attacks 
the electrophillic carbonyl of carboxylic acid 104 (Scheme 34) resulting in the alcohol 
group being liberated. The resulting intermediates 105 and 106 (Scheme 34) have azide 
functionalities which can resonate between one another as shown in Scheme 34. The 
Curtius rearrangement – initiated by heat - can be justified by the rearrangement of 
electron density of resonance structure 106. The lone pair on the nitrogen atom attacks 
the electrophillic carbonyl and forces the electron pair of the carbon-carbonyl bond to 
move onto the initiating nitrogen atom. Finally, there is the expulsion of nitrogen gas, 
resulting in isocyanates 77 and 107 (Scheme 34). It was anticipated that the 
intramolecular ring closure of the isocyanate to furnish ring B of pancratistatin would 
require a catalytic amount of Lewis acid.70 
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2.1.10 Attempted Ring Closure using isocyanate chemistry 
Compound 76 (Scheme 33) was treated with diphenyl phosphoryl azide (DPPA) and 
triethyl ammine at 0°C for ten minutes, followed by the addition of the Lewis acid - 
aluminium trichloride - and heating for 18 hours.70 TLC analysis indicated the presence 
of two compounds before the subsequent addition of the Lewis catalyst and heating. 
There were however no additional ‘spots’ formed after the treatment with aluminium 
trichloride. The reaction was worked up and only one characterizable product was 
isolated via silica gel chromatography.  
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Figure 13 Desired compound 
Unfortunately it was not possible to isolate the desired compound 78 (Figure 13). 
Analysis of the 1H NMR spectrum indicated that a compound with the majority of the 
carbon backbone present in compound 78 was indeed present in our unknown compound. 
There was no longer a broad carboxylic acid’s OH signal present on the 1H NMR 
spectrum – a broad singlet integrating for one proton at 9.00 ppm on the 1H NMR 
spectrum of compound 76 (Scheme 33). The two methyl groups belonging to the 
acetonide protecting group were still present as was indicated by two signals each 
integrating for three protons at 1.43 and 1.45 ppm on the 1H NMR spectrum of the 
unknown compound. The benzyl protecting group’s CH2 gave rise to a singlet signal 
integrating for two protons at 4.35 ppm on the 1H NMR spectrum of the attempted ring 
closure product. The CH2 group alpha to the benzyl protected oxygen gave rise to a 
double doublet at 2.98 ppm on the 1H NMR spectrum of the attempted ring closed 
product. The majority of the expected peaks required for compound 78 were included in 
the 1H NMR spectrum of the attempted ring closed product.  
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However, the aromatic region of the 1H NMR spectrum of the unknown compound did 
not correlate well with the expected signals that compound 78 (Figure 13) would have 
given rise to. Firstly, there was always an extra proton present in the aromatic region. In 
addition, there was a broad triplet signal integrating for one proton at 5.47 ppm that could 
be assigned to the proton attached to the nitrogen atom. Unfortunately, the 13C NMR 
spectrum did not resolve anything as there was only one change from the 13C NMR 
spectrum of the carboxylic acid starting material 76 (Scheme 33) and that was the shift of 
the carbonyl group’s peak from 171.2 ppm to 156.13 ppm. Otherwise all of the other 13C 
NMR spectrum peaks of our unknown compound were in the very same positions as they 
had been for the 13C NMR spectrum of compound 76. Analysis of all of the data was 
extremely frustrating as there was a lot of evidence supporting the existence of a 
compound with the majority of the carbon backbone found in compound 78. However, no 
firm conclusions could be made. Mass spectroscopy indicated the presence of a 
compound with the mass of compound 78. However there were other peaks present 
showing compounds with higher molecular masses.  The reaction was repeated without 
the presence of aluminium trichoride and the exact same compounds were isolated as 
discussed above.71      
The same chemistry was attempted on the less activated carboxylic acid 101 (Scheme 33) 
and very similar results were observed. The only difference being that the mass spectrum 
of the attempted ring closed product from compound 101 did not indicate the presence of 
the desired ring closed product.   
This was not such a bad result; in Trost’s first synthesis of                                          
pancratistatin they were unable to promote an intramolecular ring closure via the 
isocyanate to form ring B (Scheme 35).31 They reasoned that the acetonide protected 
oxygen atoms were more reactive (nucleophillic), relative to the aryl carbon, towards the 
isocyanate. This was a shortcoming in their synthesis and several steps were added to 
their synthesis as a result – see Chapter 1:Introduction, 1.4 Synthetic strategies towards 
pancratistatin – a brief history (Scheme 3).  
 
  
55 
O
O
O
O
N3
OMe
O
O
O
O
NCO
OMe
O
O
O
O
NH
OMe O
 
Scheme 35 Trost's failed use of isocyanate chemistry towards the synthesis of 
pancratistatin 
The literature showed several other examples of when the Curtius rearrangement did not 
proceed as expected. Similarly to our findings; Magnus’s group reported two inseparable 
regio-isomers 109 and 110 (7:1) when they attempted Bischler-Napieralski chemistry on 
108 to furnish ring B of pancratistatin (Scheme 36).32 The ortho position relative to the 
methoxy group was the most favourable position for ring closure. Three giants of the 
pancratistatin world: Hudlicky, Pettit and Rinner, did not experience – although un-
expectantly - regio-selectivity when they attempted the modified Bischler-Napieralski 
chemistry on the methoxy compound 111 (Scheme 37).73 They suggested that steric 
control was at play where the para position was sterically – although less electronically – 
favourable for attack.  
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Scheme 36 Magnus's inseparable regio-isomers  
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Scheme 37  Hudlicky's outcome of the modified Bischler-Napieralski reaction  
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In 2002, Kim’s group reported a very similar result to Magnus; they found that the 
modified Bischler-Napieralski reaction on 114 also yielded two inseparable isomers 115 
and 116 (7:1) (Scheme 38).74 Later in 2007, Cho  reported the formation of the two 
inseparable regio-isomers 118 and 119 (3:1) (Scheme 39).72 In lieu of what three of the 
four groups found, it was no big surprise that we would also experience regio-selectivity 
when attempting the intramolecular ring closure of 76 (Scheme 33).  
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Scheme 38 Kim's findings using Bischler-Napieralski chemistry 
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Interestingly Kim and Cho also used diphenyl phosphoryl azide and heat to convert 
carboxylic acids 120 and 123 (Scheme 40 and 41) into their corresponding isocyanates 
121 and 124 (Scheme 40 and 41) respectively. The isocyanates formed were stable and 
were then converted into their corresponding carbamates 122 and 125 (Scheme 40 and 
41). This is a possible alternative to using the Curtius rearrangement to ring close 
isocynates 77 and 107 (Scheme 34). 
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Scheme 41 Cho's use of DPPA chemistry 
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Chapter 3: Future Work and Conclusions 
 
3.1 Synthetic Successes 
 
The synthesis of all the known compounds starting with the natural tartaric acid 81 up 
until enoate 89 (Scheme 42) proceeded with great success. Starting with the natural 
tartaric acid 81 it was possible to synthesise the benzyl mono-protected compound 85 
with an overall yield of 23%. One distillation and two column purification steps were 
used up until the isolation of compound 85. It was anticipated that the use of the standard 
acid work up, using hydrochloric acid, for the reduction of compound 83 to diol 84 would 
cleave the acetonide protecting group. Subsequent attempts at removing the acteonide 
protecting group using hydrochloric acid did not work. It is thus suggested that instead of 
the somewhat tedious base work up that an acid work up be attempted for reduction of 
ester 83 to diol 84. It is anticipated that a higher yield will be achieved due to the 
simplified extraction procedure expected when an acid work up is employed. The use of 
both the activated manganese oxide and pyridium chlorochromate reactions either 
provided relatively disappointing yields and/or E:Z ratios. None the less they were 
interesting reactions to attempt. In addition it is suggested that both these reactions be re-
attempted using fresh activated manganese oxide and pyridium chlorochromate. In 
addition, the encouraging yield from the activated manganese TOP, it’s the low toxicity 
and simplicity of reaction set-up could make it a potentially useful reaction.        
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Scheme 42 Synthetic successes starting with natural tartaric acid 
 
The experience gained from the trial synthesis - using natural tartaric acid - was used to 
great effect for the attempted synthesis of pancratistatin analogues using the unnatural 
tartaric acid 69 (Scheme 43). Yields were improved for all the steps up until the 
production of the mono protected compound 73 (Scheme 43) and a total yield of 36% 
was achieved over the four steps. 
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Scheme 43 Synthetic successes starting with unnatural tartaric acid 
 
The Swern reaction – using fresh oxalyl chloride and dry triethylamine – proved to be 
great success. A respectable yield of 40% was achieved over the two steps as well as a 
decent E:Z ratio of 25:1 (Ratio calculated using the 1H NMR spectrum of 74). All of the 
reported chemistry thus far could be readily repeated with great confidence. 
 
3.2 1,4-additions using a Rhodium catalyst and Cuprate chemistry 
 
The addition of the aryl ring – ring A of pancratistatin – needed to take place with a high 
level of stereochemistry. Both the rhodium and organo cuprate chemistry were employed 
with a high level of stereo selectivity. The organo cuprate reaction was difficult to set up 
as low reaction temperatures and two cannulations were necessary. In addition, the 
purification of the desired compound 97 (Scheme 44) was tedious. However the reaction 
was an interesting and challenging task and a success in that a high yield of 86% was 
achieved with no evidence of stereoisomers being present in the product 97’s 1H NMR 
spectrum. Unfortunately a crystal structure was not obtained to indicate if the 
steroselctivity took place in an anti- or syn-selective fashion. It could be proposed from 
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the work done by Kornienko on similar systems, that the aromatic ring did add in an anti 
selective fashion.37 However more solid evidence is needed to back this claim.  
The rhodium catalysed 1,4-addition yielded a number of useful results (Scheme 45). 
Firstly, the reaction was a pleasure to set up as the reagents had to simply be mixed and 
stirred at room temperature in the presence of the starting material 74 (Scheme 45). The 
purification of the desired compounds 75 and 100 (Scheme 45) was readily done via 
silica gel column chromatography. Impressive yields and stereo-selectivity (ee >200:1) 
was achieved for both the production of compound 75 (90%) and compound 100 (95%). 
The anti-selective model proposed by Csaky was confirmed by our results as it was 
possible to obtain a crystal structure of compound 101 (Figure 11).46 It is said with great 
confidence that the rhodium catalysed reaction was more efficient in terms of it’s ease of 
set up and it is advised that this reaction be used for the installation of ring A on any 
future pancratistatin analogues produced.  
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Scheme 44 The successful use of organocuprate chemistry 
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Scheme 45 The successful use of a Rhodium catalysed reaction 
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Scheme 46 
 
Starting with tartaric acid it was possible to isolate compound 76 with an overall yield of 
11% and compound 101 with a yield of 10% (Scheme 46).  
 
3.3The attempted ring closure to furnish Ring B of our analogues 
 
Unfortunately it was not possible to identify the outcome of the ring closure reaction via 
an isocyanate intermediate and Curtius rearrangement. There is evidence to suggest that 
the isocyanate intermediates did in fact form from the characteristic N=C=O peak found 
on the IR of both the isocyanate compounds 77 and 107 (Scheme 47). However, the 1H 
and 13C NMR spectra of the isolated compounds from the attempted ring closure did not 
conclusively indicate that ring closure had taken place to furnish the protected analogues.  
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Scheme 47 Attempted ring-closure via an isocyanate intermediate and Curtius 
rearrangement 
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It is thus suggested than alternative chemistry such as Banwell’s modified Bischler-
Napieralski cyclization be attempted (Scheme 48). This is a useful synthetic alternative 
as the reaction could proceed from the carboxylic acids 76 and 101 (Scheme 46). 
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Scheme 48  An alternative for the ring closure is to try make use of Banwell’s modified 
Bischler-Napieralski cyclization chemistry 
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Chapter 4: Experimental Procedures 
 
4.1 General experimental procedures 
 
4.1.1 Purification of solvents reagents 
 
All solvents used for reactions and preparative chromatography were distilled prior to 
use. Where necessary, they were also dried by standard methods as recommended by 
Perrin et al.75 Tetrahydrofuran, was distilled from the sodium benzophenone ketyl 
radical; dichloromethane and triethylammine from calcium hydride; toluene from 
sodium; chloroform was dried from passage through basic alumina (ICN Adsorbentien, 
ICN Alumina Super I). Where necessary, solvents were stored over activated molecular 
sieves (4 Å) under nitrogen atmosphere. Unless otherwise noted, other reagents were 
obtained from commercial sources and used without purification. 
 
4.1.2 Chromatographic separations 
 
The Rf values quoted are for analytical thin layer chromatography (TLC) on aluminium 
backed Mackerey-Nagel Alugram Sil G/UV254 plates pre-coated 0.25 mm silica gel 60, 
detection by UV-adsorbtion. Preparative column chromatography was carried out on both 
wet and dry-packed columns using Macherey-Nagel Kieselgel 60 silica gel (particle size 
0.063-0.020 mm) as the adsorbent. Mixtures of EtOAc and hexane or MeOH and CH2Cl2 
were used as the mobile phase. 
 
4.1.3 Spectroscopic and physical data 
 
All melting points were obtained on a Reichert hot-stage microscope, and are 
uncorrected. 
 
1H nuclear magnetic resonance (NMR) spectra were recorded on a Bruker AVANCE 300 
(300.13 MHz) or a Bruker 400 (400.13 MHz) spectrometer.  
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Spectra were recorded in deuterated chloroform (CDCl3) and chemical shifts are reported 
in parts per million (ppm) downfield from tetramethylsilane, the internal standard; 
coupling constants are given in Hertz. Splitting patterns are designated as “s”, “d”, “t”, 
“q” and “m” indicating “singlet”, “doublet”, “triplet”, “quartet” and “multiplet” 
respectively. NMR data are reported as follows: chemical shift (integration of signal, 
splitting pattern, coupling constant(s), assignment).   
 
13C NMR (1H decoupled) spectra were recorded on a Bruker ADVANCE 300 (75.47 
MHz) or Bruker 400 (100.63 MHz) spectrometer. Spectra were recorded in CDCl3 and 
chemical shifts are reported in ppm relative to the central signal of CDCl3, taken as δ 
77.00. 
 
Infrared (IR) spectra were recorded on a Bruker IFS-25 Fourier Transform spectrometer. 
The signals are reported on the wavenumber scale (ν/cm-1). Signals were designated as 
“s”, “m”, “w” and “br”; indicating “strong”, “medium”, “weak” and “broad” respectively. 
IR spectra data are reported as follows: wavenumber (intensity, assignment). 
 
High resolution mass spectra were recorded on a Kratos MS 9/50, VG 70E MS or a VG 
70 SEQ mass spectrometer. 
 
Optical rotations were measured on a Jasco DIP 3-70 instrument at 19 °C at the sodium D 
line, and [α]D are given in deg.cm2.g-1. 
 
4.1.4 Crystal structure solution and refinement 
 
Intensity data were collected at 20 °C on a Bruker SMART 1K CCD area detector 
diffractometer with graphite monochromated Mo Kα radiation (50 kV, 30 mA). The 
collection method involved ω-scans of width 0.3 °. Data reduction was carried out using 
the program SAINT+ and adsorption corrections were made using the program 
SADABS.76
 
The crystal structure was solved by direct methods using SHELXTL.77  
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Non hydrogen atoms were first refined isotropically followed by an anistropic refinement 
by full matrix least squares calculations based on F2 using SHELXTL. Hydrogen atoms 
were positioned geometrically and allowed to ride on their respective parent atoms. 
Diagrams and publication material generated using SHELXTL and PLATON.78 
 
4.1.5 Other general procedures 
 
The term “in vacuo” refers to the removal of solvent by rotary evaporation, followed by 
removal of the residual solvent at the oil pump’s pressure (ca. 0.1-1 Torr) at ambient 
temperature or with heat applied from a hair dryer until constant mass was achieved. 
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4.2 Experimental procedures 
 
4.2.1 Synthesis of (2R,3R)-Dimethyl 2,3-dihydroxysuccinate 82  
 In a flame dried, 100 cm3 round-bottom flask fitted with a 
condenser, L(+)-tartaric acid (20.00 g, 133 mmol) was dissolved in 
anhydrous methanol (60 cm3). The solution was then placed in an 
ice-bath and cooled to 0 °C. Thionyl chloride (50.5 cm3, 82.00 g, 689 
mmol, 5.2 equiv.) was added drop-wise over 1 h to the cooled solution. The reaction 
mixture was allowed to warm up to room temperature and subsequently heated at reflux 
for 18 hours. The reaction mixture was allowed to cool to room temperature and the 
solvent was removed in vacuo. The resulting orange-yellow residue was washed with 
distilled water (40 cm3) and extracted with ethyl acetate (3 × 40 cm3). The combined 
organic extracts were then dried with anhydrous Na2SO4 and solvent then removed in 
vacuo, to yield a light yellow oil (20.48 g, 86%). Rf = 0.7 (5% CH3OH/CHCl3); IR : νmax-
(cm-1) = 3480 (s, br, OH), 1735 (s, C=O); 1H NMR (300 MHz, CDCl3): δH = 4.54 (2H, s, 
1-CH and 2-CH), 3.82 (6H, d, J = 1.5 Hz, 9-CH3 and 12-CH3), 3.51 (2H, bs, 3-OH and 4-
OH); 13C  NMR (75 MHz, CDCl3) δC = 170.0 (C-5 and C-6), 70.2 (C-1 or C-2), 70.2 (C-
1 or C-2), 51.14 (C-9 or C-12), 51.12 (C-9 or C-12). 
4.2.2 Synthesis of (4R,5R)-Dimethyl 2,2-dimethyl-1,3-dioxolane-4,5-dicarboxylate 83 
(2R,3R)-Dimethyl 2,3-dihydroxysuccinate 82 (20.4 g, 114 mmol) 
was dissolved distilled DMF (60 cm3). 2,2-Dimethoxy propane (160 
cm3 , 1.13 mol, 10 equiv.) and a catalytic amount of  p-toluene 
sulphonic acid monohydrate (1.30 g, 6.85 mmol, 16.6 mol %) was 
added to the solution. The reaction mixture was then heated at reflux for 18 h. The 
reaction mixture was allowed to cool to room temperature and the organic solvents were 
removed in vacuo until approximately 50 cm3 of a dark red solution remained. 50 cm3 4% 
aqueous NaHCO3 solution was added and the organic material extracted with CHCl3 (6 × 
50 cm3). The organic extracts were combined, dried using anhydrous Na2SO4 and the 
solvent removed in vacuo to yield a dark red-orange liquid. The desired compound (15.9 
1 2
HO
3
OH
4
56
O
O
9O
O
12
  
69 
g, 60 %), a light yellow oil, was obtained via distillation (bp = 130 °C at 6 mbar). Rf = 0.9 
(5% CH3OH/CHCl3); 1H NMR (300 MHz, CDCl3): δH = 4.81 (2H, s, 10-CH and 13-CH), 
3.83 (6H, s, 4-CH3 and 5-CH3), 1.49 (6H, s, 2-CH3 and 3-CH3); 13C NMR (75 MHz, 
CDCl3) δC =  170.4 (C-6 and C-14), 114.2 (C-1), 77.3 (C-10 and C-13), 53.1 (C-4 and C-
5), 26.6 (C-2 and C-3). 
 
4.2.3 Synthesis of [(4S,5S)-2,2-Dimethyl-1,3-dioxolane-4,5-diyl]dimethanol 84 
 
A mixture of LiAlH4 (5.75 g, 151 mmol, 2.2 equiv.) in anhydrous 
Et2O (90 cm3) was heated vigorously at reflux for 30 min. It is 
important to note that the mixture needed to be stirred vigorously and 
that all glassware and the Et2O be free of water. The mixture was then 
cooled to room temperature. (4R,5R)-Dimethyl 2,2-dimethyl-1,3-dioxolane-4,5-
dicarboxylate 83 (15.0 g, 68.5 mmol) was dissolved in anhydrous Et2O (90 cm3) and 
added drop-wise to the LAlH4-Et2O mixture over 1 h. The reaction mixture was 
subsequently heated at reflux for 18 h. On cooling, the reaction mixture was quenched, 
by with the cautious addition of H2O (10 cm3), 4M NaOH (25 cm3) and finally H2O (20 
cm3). The grey colloidal solid that formed was allowed to dry overnight. The resulting 
solid grey reaction mixture was subsequently ground to a powder and the organic 
compounds were removed by passing hot Et2O through the powder. The organic extracts 
were removed in vacuo. The desired product (7.54 g, 68%) was then obtained by column 
chromatography. The undesired compounds were initially removed from the column 
using 5% MeOH/CH2Cl2 and the desired compound was eluted from the column using 
MeOH. It was necessary to remove silica from the effluent using CH2Cl2 and filtration. 
Rf = 0.15 (5% CH3OH/CHCl3); 1H NMR (300 MHz, CDCl3): δH = 3.94 – 3.97 (2H, m, 
10-CH and 11-CH), 3.69 – 3.79 (4 H, m, 6-CH2 and 8-CH2), 3.01 (2H, bs, 1-OH and 5-
OH), 1.42 (6H, s, 3-CH3 and 4-CH3); 13C NMR (75 MHz, CDCl3) δC = 109.7 (C-7), 78.7 
(C-10 and C-11), 62.5 (C-6 and C-8), 27.4 (C-3 and C-4). 
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4.2.4 Synthesis of ((4S,5S)-5-(Benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-4-
yl)methanol 85 
 
A suspension of NaH (0.739 g, 18.4 mmol, 1.2 equiv.) in 
THF (20 cm3) was made and cooled to 0 °C.  [(4S,5S)-
2,2-Dimethyl-1,3-dioxolane-4,5-diyl]dimethanol 84 (2.5 
g, 15 mmol) was dissolved in THF (10 cm3) and added 
cautiously over 15 min. to the suspension. The reaction mixture was then warmed to and 
stirred at room temperature for 1 h. Further portions of THF (2 × 30 cm3) were added to 
break up the suspension and assist the stirring. The precipitate, sodium (4S,5R)-5-
Carboxy-2-methyl-1,3-dioxolane-4-carboxylate, was evidently forming. Benzyl bromide 
(2.0 cm3, 2.9 g, 17 mmol, 1.1 equiv.) was dissolved in THF (10 cm3) and added to the 
reaction mixture over a period of 10 min. The reaction mixture was then stirred for 17 h 
at room temperature. The formation of a white salt, NaBr, was observed. The reaction 
was quenched with saturated NH4Cl (50 cm3) and saturated NaCl (40 cm3). Extraction of 
the organic solutes was done using Et2O (2 × 50cm3). The organic extracts were then 
combined and dried using Na2SO4 and the solvent removed in vacuo to yield a yellow oil. 
The undesired side-products were removed using silica gel column chromatography (15% 
ethyl acetate/hexane) and the desired product, a light yellow oil (2.56 g, 66%), was eluted 
from the column (5% MeOH/CH2Cl2). Using an isovannilin staining dip, the product 
could be clearly seen on a TLC plate as a blue spot. Rf = 0.1 (20% EtOAc/Hexane); 1H 
NMR (300 MHz, CDCl3): δH = 7.26 – 7.37 (5H, m, 5 × A-H’s), 4.58 (2H, s, 8-CH2), 4.03 
(1H, td, J =  8.1, 5.3 Hz, 10-CH), 3.94 (1H, td, J = 8.3, 4.3 Hz, 13-CH), 3.76 (1H, dd, J = 
11.7, 4.1 Hz, 6-CH2), 3.70 (1H, d, J = 4.9 Hz, 6-CH2), 3.7 (1H, d, J = 5.0 Hz, 8-CH2), 
3.56 (1H, dd, J = 9.9, 5.6 Hz, 8-CH2), 2.42 (1H, s, 11-OH), 1.41 (6H, s, 2-CH3 and 3-
CH3); 13C NMR (75 MHz, CDCl3) δC = 137.9 (C-19), 128.9 (C-21 and C-23), 128.3 (C-
22), 128.2 (C-20 and C-24), 109.8 (C-1), 80.1 (C-13), 76.9 (C-10), 74.1 (C-8), 70.8 (C-
9), 62.8 (C-6), 27.4 (C-2 and C-3). 
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4.2.5 Synthesis of (E)-Methyl 3-((4R,5S)-5-(benzyloxymethyl)-2,2-dimethyl-1,3-
dioxolan-4-yl)acrylate 89  
 
Method 1 
 
A solution of [(4S,5S)-5-(Benzyloxymethyl)-2,2-dimethyl-
1,3-dioxolan-4-yl)]methanol 85 (0.086 g, 0.343 mmol), 90% 
(triphenylphosphoranylidene)acetate (0.139 g, 0.375 mmol, 
1.1 equiv.) and CH2Cl2 (10 cm3) was prepared. Activated 90% 
manganese oxide (0.331 g, 3.43 mmol, 10 equiv.) was added 
to the solution and the reaction mixture was heated to reflux. After 4 h a further portion 
of activated manganese oxide (0.166 mg, 1.71 mmol) was added to the reaction mixture. 
The reaction mixture was heated at reflux for 24 h. The reaction mixture was then filtered 
through celite and the organic solvent removed in vacuo. Silica gel chromatography (20% 
EtOAc/hexane) was used to purify the product (0.042 g, 40%). E:Z = 3.5:1; Rf = 0.4 
(20% EtOAc/hexane); 1H NMR (300 MHz, CDCl3): δH = 7.18 - 7.28 (5H, m, 5 × A-H’s), 
6.84 (1H, dd, J = 15.7, 5.3 Hz, 6-CH), 5.95 (1H, dd, J = 15.7, 0.7 Hz, 8-CH), 4.52 (2H, s, 
12-CH2), 4.36 (1H, dd, J = 8.3, 5.4 Hz, 5-CH), 3.88 (1H, td, J = 8.8, 4.5 Hz, 4-CH), 3.67 
(3H, s, 22-CH3), 3.56 (2H, d, J = 4.8 Hz, 1-CH2), 1.37 (6H, d, J = 7.3 Hz, 10-CH3 and 11-
CH3). 
 
Method 2 
 
A suspension of PCC (0.261 g, 1.18 mmol, 1.5 equiv.), sodium acetate (0.985 g, 1.18 
mmol, 1.5 equiv.) and CH2Cl2 (10 cm3) was made. A solution of [(4S,5S)-5-
(Benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)]methanol 85 (0.200 g, 0.792 mmol) 
in CH2Cl2 (5 cm3) was added to the suspension. The reaction mixture was then stirred for 
10 min. before 90% (triphenylphosphoranylidene)acetate (0.278 mg, 0.792 mmol, 1 
equiv.) was added. The reaction mixture was then stirred at room temperature for 20 h. A 
further portion of PCC (0.087 g, 0.393 mmol, 0.5 equiv.) was added and the reaction 
mixture was stirred for a further 6 h. The reaction mixture was subsequently filtered 
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through celite and the organic solvent removed in vacuo. Purification was performed 
using silica gel column chromatography (20% EtOAc/hexane) to yield the desired 
product as clear oil (0.020 g, 8.2%). E:Z = 8:1. Rf = 0.4 (20% EtOAc/hexane); 1H NMR 
(300 MHz, CDCl3): δH = 7.19 – 7.30 (5H, m, 5 × A-H’s), 6.84 (1H, dd, J = 15.7, 5.3 Hz, 
6-CH), 5.95 (1H, dd, J = 15.7, 0.70 Hz, 8-CH), 4.52 (2H, s, 12-CH2), 4.36 (1H, dd, J = 
7.4, 6.2 Hz, 5-CH), 3.73 – 3.90 (1H, m, 4-CH), 3.67 (3H, s, 22-CH3), 3.56 (2H, d, J = 4.7 
Hz, 1-CH2), 1.37 (6H, d, J = 7.3 Hz, 10-CH3 and 11-CH3). 
 
4.2.6 Synthesis of (2S,3S)-Dimethyl 2,3-dihydroxysuccinate 70  
 
In a flame-dried round bottom flask fitted with a condenser, D-(-)-
tartaric acid (20.0 g, 133 mmol) was dissolved in anhydrous 
methanol (80 cm3). The solution was placed in an ice-bath and 
cooled to 0 °C. Thionyl chloride (50.5 cm3, 82 g, 689.2 mmol, 5.2 
equiv.) was added drop-wise over 1 h to the cooled solution. The reaction mixture was 
allowed to warm up to room temperature and subsequently heated at reflux for 18 h. The 
reaction mixture was allowed to cool to room temperature and the solvents were removed 
in vacuo. The resulting orange-yellow residue was washed with distilled water (40 cm3) 
and extracted with ethyl acetate (3 × 40 cm3). The organic extracts were dried with 
anhydrous Na2SO4 and the organic solvent was removed in vacuo to yield a light yellow 
oil (20.64 g, 87%). Rf = 0.7 (5% CH3OH/CHCl3); IR : νmax(cm-1) = 3480 (s, br, OH), 
1735 (s, C=O); 1H NMR (300 MHz, CDCl3): δH = 4.33 (2H, s, 1-CH and 2-CH), 3.59 
(6H, s, 11-CH3 and 12-CH3), 3.43 (2H, bs, 3-OH and 4-OH); 13C  NMR (75 MHz, 
CDCl3) δC = 172.3 (C-5 and C-6), 72.5 (C-1 and C-2), 53.3 (C-11 and C-12); ESIMS m/z 
(relative intensity) 179 (M+ +1, 4), 172 (8), 129 (10), 73 (32). 
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4.2.7 Synthesis of (4S,5S)-Dimethyl 2,2-dimethyl-1,3-dioxolane-4,5-dicarboxylate 71  
 
(2S,3S)-Dimethyl 2,3-dihydroxysuccinate 70 (20.4 g, 114 mmol) was 
dissolved in distilled DMF (60 cm3). 2,2-dimethoxy propane (160 
cm3, 1.13 mol) and a catalytic amount of  p-toluene sulphonic acid 
monohydrate (1.30 g, 6.85 mmol) was added to the solution. The 
reaction mixture was heated at reflux for 18 h. The reaction mixture was allowed to cool 
to room temperature before the organic solvents were removed in vacuo until 
approximately 50 cm3 of a dark red solution remained. 4% aqueous NaHCO3 solution (50 
cm3) was added and the organic material extracted with CHCl3 (6 × 50 cm3). The organic 
extracts were combined, dried using anhydrous Na2SO4 and the solvent removed in vacuo 
to yield a dark orange liquid. The desired compound (15.7 g, 65 %), a light yellow oil, 
was obtained via distillation (bp = 130 °C at 6 mbar). [α]25D + 41.8, EtOAc, c = 54 
mg.ml-1 (lit.79 [α]20D + 44.0, no solvent); Rf = 0.9 (5% CH3OH/CHCl3); IR : νmax(cm-1) = 
1740 (s, C=O), 1206 (s, C-O); 1H NMR (300 MHz, CDCl3): δH = 4.81 (2H, s, 1-CH and 
2-CH), 3.83 (6H, s, 3-CH3 and 4-CH3), 1.49 (6H, s, 12-CH3 and 13-CH3); 13C NMR (75 
MHz, CDCl3) δC =  170.4 (C-5 and C-6), 114.2 (C-11), 77.3 (C-1 and C-2), 53.1 (C-3 and 
C-4), 26.7 (C-12 and C-13); ESIMS m/z (relative intensity) 179 (M+ +1, 4),  
 
4.2.8 Synthesis of [(4R,5R)-2,2-Dimethyl-1,3-dioxolane-4,5-diyl]dimethanol 72 
 
A mixture of LiAlH4 (5.75 g, 151.4 mmol) and anhydrous Et2O 
(90 cm3) was heated vigorously at reflux for 30 min. It is 
important to note that the mixture needs to be stirred vigorously 
and that all glassware and the Et2O be free of water. The mixture 
was then allowed to cool to room temperature. (4S,5S)-Dimethyl 2,2-dimethyl-1,3-
dioxolane-4,5-dicarboxylate 71 (14.96 g, 68.5 mmol) was dissolved in anhydrous Et2O 
(90 cm3) and added drop-wise over 1 h. The reaction mixture was subsequently heated at 
reflux for 18 h. On cooling, the reaction mixture was quenched, by carefully adding H2O 
(10 cm3), 4M NaOH (25 cm3) and finally H2O (20 cm3). The resulting grey colloidal 
matter that formed was allowed to dry overnight. The resulting solid grey was then 
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ground to a powder. The organic compounds were removed by passing hot Et2O through 
the powder and finally the Et2O was removed in vacuo. The desired product (7.69 g, 
70%) was obtained by column chromatography. The undesirable compounds were 
removed from the column using 5% MeOH/CH2Cl2 and the desired compound was eluted 
from the column using MeOH. It was necessary to remove silica from the effluent with 
CH2Cl2 and filtration. [α]25D -9.6, EtOAc, c = 60 mg.ml-1 (lit.80 [α]26D – 4.8, CHCl3, c = 
10 mg.ml-1); Rf = 0.9 (5% CH3OH/CHCl3); IR : νmax(cm-1) = 3389 (s, b, OH), 1215 (s, C-
O); 1H NMR (300 MHz, CDCl3): δH = 3.97 (2H, tt, J = 2.7, 1.56 Hz, 1-CH and 2-CH), 
3.67 – 3.78  (4 H, m, 5-CH2 and 6-CH2), 3.09 (2H, t, J = 5.7 Hz, 7-OH and 8-OH), 1.42 
(6H, s, 10-CH3 and 11-CH3); 13C NMR (75 MHz, CDCl3) δC = 107.5 (C-9), 70.5 (C-1 
and C-2), 60.4 (C-5 and C-6), 25.2 (C-10 and C-11).  
 
4.2.9 Synthesis of ((4R,5R)-5-(Benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-4-
yl)methanol 73   
 
A suspension of NaH (0.739 g, 18.4 mmol, 1.2 equiv.) in 
THF (20 cm3) was made and cooled to 0 °C. [(4R,5R)-2,2-
Dimethyl-1,3-dioxolane-4,5-diyl]dimethanol 72 (7.5 g, 
46.2 mmol) was dissolved in THF (30 cm3) and added 
cautiously over 1 h to the suspension. The reaction mixture was then warmed to, and 
stirred at room temperature for 1 h. Further portions of THF (2 × 30 cm3) were added to 
break up the suspension and assist stirring. The precipitate, sodium [(4R,5R)-5-
(Benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl]methanolate, was evidently forming. 
Benzyl bromide (6.0 cm3, 8.7 g, 50 mmol, 1.1 equiv.) was dissolved in THF (25 cm3) and 
added to the reaction mixture over a period of 10 min. The reaction mixture was stirred 
for 20 h at room temperature and the formation of a white salt, NaBr, was observed. The 
reaction was quenched with saturated aqueous NH4Cl solution (40 cm3) and saturated 
NaCl solution (40 cm3). Extraction was accomplished using Et2O (4 × 50 cm3)  and the 
extracts were combined and dried using Na2SO4 and the solvent removed in vacuo. This 
yielded a yellow oil. The unwanted side products were removed via silica gel column 
chromatography (15% Ethyl acetate/Hexane) and the desired product, a light yellow oil 
12
O
O
9 8
7
O
OH 14
15
16
17
18
19
20
21
22
23
24
  
75 
(10.13 g, 80%), was eluted from the column (5% MeOH/CH2Cl2). Using an isovanilin 
staining dip, the product could be clearly seen on a TLC plate as a blue spot. [α]25D + 1.7, 
EtOAc, c = 23 mg.ml-1 (lit.81 [α]26D – 9.3, CHCl3, c = 14.4 mg.ml-1); Rf = 0.1 (20% 
EtOAc/Hexane); IR : νmax(cm-1) = 3466 (s, b, OH), 1214 (s, C-O), 1497 (w, C=C 
aromatic); 1H NMR (300 MHz, CDCl3): δH = 7.26 – 7.34 (5H, m, 5 * A-H’s), 4.58 (2H, 
s, 18-CH2), 4.02 – 4.15 (1H, m, 9-CH), 3.91 – 3.99 (1H, m, 8-CH), 3.77 (1H, dd, J = 
11.5, 4.2 Hz, 7-CH2), 3.72 (1H, d, J = 7.5 Hz, 7CH2), 3.68 (1H, d, J = 5.2 Hz, 12-CH2), 
3.55 (1H, dd, J = 9.9, 5.7 Hz, 12-CH2), 2.32 - 2.36 (1H, m, 14-OH), 1.41 (6H, s, 16-CH3 
and 17-CH3); 13C NMR (75 MHz, CDCl3) δC = 137.6 (C-19), 128.5 (C-21 and C-23), 
127.9 (C-22), 127.8 (C-20 and C-24), 109.4 (C-15), 79.7 (C-8), 76.6 (C-9), 73.7 (C-18), 
70.4 (C-12), 62.5 (C-7), 27.0 (C-16 or C-17), 27.0 (C-16 or C-17); HRMS: Found [M-
CH3]+, 237.1128. C13H17O4 requires M 237.1132; m/z (EI) 237 ([M-CH3]+, 2%), 235 (2), 
221 (11). 
 
4.2.10 Synthesis of (E)-Methyl 3-((4R,5R)-5-(benzyloxymethyl)-2,2-dimethyl-1,3-
dioxolan-4-yl)acrylate 74 
 
Oxalyl chloride (8.24 cm3, 11.8 g, 92 mmol, 2 equiv.) was 
dissolved in anhydrous CH2Cl2 (50 cm3) and cooled to -60 
°C. A solution of dimethyl sulphoxide (DMSO) (13.2 cm3, 
14.5 g, 4 equiv.) in and anhydrous CH2Cl2 (50 cm3) was 
carefully added drop-wise, over a period of 10 min, to the 
oxalyl chloride solution. Furthermore, a solution of [(4R,5R)-
5-(Benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-4-
yl]methanol 73 (11.7 g, 46.3 mmol) in anhydrous CH2Cl2 (50 cm3) was then added. The 
reaction mixture was stirred for 15 min. before triethyl amine (32.3 cm3, 23.4 g, 231 
mmol, 5.1 equiv.) was added. The reaction mixture was then slowly warmed to room 
temperature over 10 min. The organic solvent was removed in vacuo to yield a bright 
yellow oil. A quantitative yield was assumed and the crude aldehyde was used without 
delay. A suspension of 60% sodium hydride (2.4 g, 60 mmol) in anhydrous THF (50 cm3) 
was stirred at -20 °C for 10 min. Trimethyl phosphonoacetate (8.7 cm3, 10.9 g, 60 mmol, 
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1.3 equiv.), dissolved in THF (30 cm3), was then added to the suspension at -20 °C. The 
reaction mixture was stirred at -20 °C for 1 h. Further portions of THF were added to 
assist stirring; as more precipitate had formed. The aldehyde, [(4S,5R)-5-
(Benzyloxymethyl)-2,2-dimethyl-1,3-dioxolane-4-carbaldehyde, was dissolved in THF 
(20 cm3) and added to the reaction mixture. The mixture was stirred at -20 °C for 1 h 
before being allowed to warm slowly to room temperature overnight. The THF was 
removed in vacuo. H2O (50 cm3) was then added to the yellow residue and the organic 
material extracted with EtOAc (3 × 70 cm3). The organic extracts were dried using 
Na2SO4 and the solvent removed in vacuo. The desired product was purified by silica gel 
column chromatography (15% EtOAc/hexane) to yield a bright yellow oil (5.9 g, 42% 
over two steps) E:Z = 25:1 . [α]25D + 22.2 (MeOH, c = 21 mg.ml-1) Rf = 0.33 (15% 
EtOAc/Hexane); IR : νmax(cm-1) = 1726 (s, C=O), 1664 (w, C=C); 1H NMR (300 MHz, 
CDCl3): δH = 7.26 – 7.37 (5H, m, Aromatic H’s), 6.91 (1H, dd, J = 15.7, 5.6 Hz, 6-CH), 
6.11 (1H, dd, J = 15.7, 1.4 Hz, 8-CH), 4.58 (2H, s, 12-CH2), 4.43 (1H, ddd, J = 8.3, 5.4, 
1.3 Hz, 5-CH), 3.95 (1H, td, J = 8.5, 4.8 Hz, 4-CH), 3.73 (3H, s, 22-CH3), 3.63 (2H, dd, J 
= 4.5, 0.9 Hz, 1-CH2), 1.44 (6H, d, J = 7.3, 10-CH3 and 11-CH3); 13C NMR (75 MHz, 
CDCl3) δC = 166.3 (C-19), 144.4 (C-6), 137.7 (C-13), 128.3 (C-15 and C-17), 127.7 (C-
16), 127.6 (C-14 and C-18), 121.9 (C-8), 110.1 (C-9), 79.5 (C-5), 77.4 (C-4), 73.6 (C-
12), 69.2 (C-1), 51.6 (C-22), 26.9 (C-10 or C-11), 26.6 (C-10 or C-11). 
 
 4.2.11 Synthesis of Methyl 3-((4R,5R)-5-(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-
4-yl)-3-phenylpropanoate 97  
 
Magnesium turnings (0.388 g, 16 mmol, 10 equiv.) was 
added to anhydrous THF (15 cm3). Phenyl bromide (1.7 
cm3, 2.49 g, 16 mmol, 10 equiv.) dissolved in anhydrous 
THF (5 cm3) was then added. The reaction mixture was 
left to stand without stirring for approximately 20 min. 
Stirring was started once one could feel heat being 
generated by the reaction mixture. The reaction was stirred for approximately 30 min. or 
until the reaction mixture cooled down - indicating the reaction was complete. Copper 
1 O
O45
6
O
8
9 10
11
12
O
O
15
1617
18
19 20
21
22
23
24
25
26
27
28
  
77 
iodide (1.52 g, 8 mmol, 5 equiv.) was mixed with anhydrous THF (15 cm3) and cooled to 
-65 °C. Please note that the copper (I) iodide was purified using hot THF flushing. The 
Grignard previously prepared was then cannulated into the cooled copper (I) iodide/THF 
mixture. The reaction mixture was stirred for 1 h at -60 °C. (E)-methyl 3-((4R,5R)-5-
(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)acrylate 74 (0.490 g, 1.6 mmol) was 
dissolved in anhydrous THF (15 cm3) and cannulated to the reaction mixture. The 
reaction mixture was warmed slowly to room temperature and stirred for 20 h. Saturated 
aqueous NH4Cl solution (3 × 50 cm3) was used to quench the reaction and EtOAc (3 × 50 
cm3) was used to extract the organic component. The organic extracts were combined and 
dried with Na2SO4 and the solvent removed in vacuo. The product (1.72 g, 86%) was 
isolated using silica gel column chromatography (10% EtOAc/hexane) as yellow tinted 
clear oil. Rf = 0.45 (15% EtOAc/hexane); 1H NMR (300 MHz, CDCl3): δH = 7.15 – 7.28 
(10H, m, 10 × A-H’s), 4.28 (2H, d, J = 1.1 Hz, 22-CH2), 3.88 – 3.98 (2H, m, 1-CH2), 
3.53 (3H, s, 21-CH3), 3.26 (1H, ddd, J = 9.5, 8.7, 5.1 Hz, 5-CH), 3.06 (1H, dd, J = 15.7, 
5.0 Hz, 4-CH), 2.76 – 2.85 (2H, m, 8-CH2), 2.68 (1H, dd, J = 15.7, 9.9 Hz, 6-CH), 1.43 
(6H, d, 6.1 Hz, 10-CH3 and 11-CH3); 13C NMR (75 MHz, CDCl3) δC = 173.4 (C-12), 
139.8 (C-15), 138.4 (C-23), 129.9 (C-17 and C-19), 129.1 (C-18), 128.7 (C-16 and C-20), 
128.5 (C-25 and C-27), 128.0 (C-26), 127.9 (C-24 and C-28), 109.7 (C-9), 80.5 (C-5), 
80.4 (C-4), 73.6 (C-22), 70.7 (C-1), 51.9 (C-21), 47.2 (C-8), 38.6 (C-6), 27.6 (C-10 or C-
11), 27.5 (C-10 or C-11); HRMS: Found [M-CH3]+, 369.1697. C22H25O5 requires M 
369.1697; m/z (EI) 369 ([M-CH3]+, 100%), 366 (44), 364 (6), 359 (10), 355 (40). 
 
4.2.12 Synthesis of Methyl 3-(benzo[d][1,3]dioxol-5-yl)-3-((4R,5R)-5-
(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)propanoate 75  
 
A mixture of 3,4-(Methylene dioxy)-phenyl boronic 
acid (0.539 g, 3.6 mmol, 2 equiv.) and [(cod)RhCl]2 
(0.035 g, 0.060 mmol, 4.2 mol %) was made.  
Methyl (2E)-6-O-(1,3-cyclohexadien-1-ylmethyl)-2,3-
dideoxy-4,5-O-(1-methylethylidene)-L-erythro-hex-2-
enonate 74 (0.5 g, 1.6 mmol) was dissolved in, 
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thoroughly degassed 1,4-dioxane/H2O (10:1) (5 cm3), and added to the solid mixture. 
Triethyl amine (0.3 cm3, 1.8 mmol, 1.1 equiv) was then added to the above mixture. The 
reaction mixture was stirred for 18 h. The solvents were removed in vacuo and the crude 
product dried onto silica. The product (0.627 g, 90%), an orange-yellow oil, was purified 
by silica gel column chromatography (15% EtOAc/hexane). [α]25D + 50.7 (MeOH, c = 13 
mg.ml-1); Rf = 0.42 (20% EtOAc/hexane); IR : νmax(cm-1) = 1735 (s, C=O); 1H NMR 
(300 MHz, CDCl3): δH = 7.18 – 7.36 (5H, m, 5 × A-H’s), 6.60 – 6.68 (3H, m, 16-CH, 19-
CH and 20-CH), 5.90 (1H, m, 23-CH2), 5.88 (1H, m, 23-CH2), 4.36 (2H, s, 24-CH2), 3.85 
– 3.94 (2H, m, 1-CH2), 3.55 (3H, s, 31-CH3), 3.18 (1H, dt, J = 9.8, 9.7, 4.8 Hz, 5-CH), 
3.01 (1H, dd, J = 15.7, 4.7 Hz, 4-CH), 2.94 (2H, t, J = 3.67 Hz, 8-CH2), 2.59 (1H, dd, J = 
15.7, 10.1 Hz, 6-CH), 1.42 (6H, d, J = 5.6 Hz, 10-CH3 and 11-CH3); 13C NMR (75 MHz, 
CDCl3) δC = 172.4 (C-12), 147.8 (C-17), 146,7 (C-18), 137.9 (C-25), 133.2 (C-15), 128.2 
(C-27 and C-29), 127.5 (C-28), 127.5 (C-26 and C-30), 121.4 (C-20), 109.2 (C-19), 108.4 
(C-16), 108.2 (C-9), 100.9 (C-23), 80.1 (C-5), 79.9 (C-4), 73.2 (C-24), 70.4 (C-1), 51.5 
(C-31), 46.4 (C-8), 38.3 (C-6), 27.2 (C-10 or C-11), 27.2 (C-10 or C-11). 
 
4.2.13 Synthesis of Methyl 3-((4R,5R)-5-(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-
4-yl)-3-phenylpropanoate 100  
 
A mixture of phenylboronic acid (0.394 g, 3.3 mmol, 2 
equiv.) and [(cod)RhCl]2 (0.022 g, 0.044 mmol, 2.7 mol 
%) was made. (E)-Methyl 3-((4R,5R)-5 
(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-4-
yl)acrylate 74 (0.5 g, 1.6 mmol) was dissolved in, 
thoroughly degassed, 90% 1,4-dioxane/H2O (5 cm3) and 
added to the boronic acid and rhodium catalyst mixture. Triethyl amine (0.25 cm3, 1.8 
mmol, 1.1 equiv) was added to the above mixture. The reaction mixture was stirred for 18 
h. The solvents were removed in vacuo and the crude product dried onto silica. The 
product (0.590 g, 95%), a yellow oil, was purified by silica gel column chromatography 
(15% EtOAc/hexane). [α]25D + 37.9 (MeOH, c = 11 mg.ml-1); Rf = 0.40 (20% 
EtOAc/Hexane); IR : νmax(cm-1) = 1736 (s, C=O) 1496 (w, C=C aromatic); 1H NMR 
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(300 MHz, CDCl3): δH = 7.15 – 7.29 (10H, m, 10 × A-H’s), 4.27 (2H, s, 22-CH2), 3.88 – 
3.97 (2H, m, 1-CH2), 3.52 (3H, s, 21-CH3), 3.26 (1H, dt, J = 9.2, 8.8, 5.1 Hz, 5-CH), 3.06 
(1H, dd, J = 15.7, 4.9 Hz, 4-CH), 2.79 – 2.82 (2H, m, 8-CH2), 2.68 (1H, dd, J = 15.7, 9.9 
Hz, 6-CH), 1.43 (6H, d, J = 6.3 Hz, 10-CH3 and 11-CH3); 13C NMR (75 MHz, CDCl3) δC 
= 171.4 (C-12), 138.3 (C-15), 136.9 (C-23), 128.2 (C-17 and C-19), 127.6 (C-18), 127.1 
(C-16 and C-20), 126.9 (C-25 and C-27), 126.5 (C-26), 126.4 (C-24 and C-28), 108.10 
(C-9), 78.9 (C-5), 78.9 (C-4), 72.1 (C-22), 69.2 (C-1), 50.4 (C-21), 45.7 (C-8), 37.1 (C-
6), 26.1 (C-10 or C-11).    
 
4.2.14 Synthesis of 3-(Benzo[d][1,3]dioxol-5-yl)-3-((4R,5R)-5-(benzyloxymethyl)-2,2-
dimethyl-1,3-dioxolan-4-yl)propanoic acid 76  
 
Methyl 3-(benzo[d][1,3]dioxol-5-yl)-3-((4R,5R)-5-
(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-4-
yl)propanoate 75 (0.460 g, 1.1 mmol) was dissolved 
in MeOH (30 cm3). 5% aqueous KOH solution (20 
cm3) was added to the reaction mixture. The reaction 
mixture was stirred for 18 h at room temperature. The 
organic solvent was removed in vacuo. Saturated aqueous NaHCO3 solution (50 cm3) was 
added to the pale yellow residue and washed with Et2O (50 cm3). The aqueous extract 
was collected and cooled to 0 °C. 10% aqueous HCl solution was carefully added to the 
aqueous extract until the mixture was acidified – acidity was monitored with pH paper. 
The desired carboxylic acid (0.420 g, 95%) was extracted with EtOAc (3 × 50 cm3) and 
dried over Na2SO4 and the solvent was finally removed in vacuo. [α]25D + 25.8 (MeOH, c 
= 16 mg.ml-1) Rf = 0 (20% EtOAc/hexane); IR : νmax(cm-1) = ; 1H NMR (300 MHz, 
CDCl3): δH = ≈ 9.00 (1H, bs, 14-OH), 7.17 – 7.32 (5H, m, 5 × A-H’s), 6.58 – 6.65 (3H, 
m, 16-CH, 19-CH and 20-CH), 5.89 (1H, m, 23-CH2), 5.87 (1H, m, 23-CH2), 4.35 (2H, s, 
24-CH2), 3.82 – 3.93 (2H, m, 1-CH2), 3.13 (1H, dt, J = 9.4, 9.2, 5.2 Hz, 5-CH), 3.03 (1H, 
dd, J = 16.0, 4.0 Hz, 4-CH), 2.91 (2H, d, J = 3.9, 8-CH2), 2.58 (1H, dd, J = 15.8, 9.9 Hz, 
6-CH), 1.40 (6H, d, J = 2.3 Hz, 10-CH3 and 11-CH3); 13C NMR (75 MHz, CDCl3) δC = 
171.2 (C-12), 147.8 (C-17), 146.7 (C-18), 137.9 (C-25), 132.9 (C-15), 128.2 (C-27 and 
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C-29), 127.5 (C-28), 127.5 (C-26 and C-30), 121.3 (C-20), 109.3 (C-19), 108.4 (C-16), 
108.2 (C-9), 100.9 (C-23), 79.9 (C-5), 79.9 (C-4), 73.2 (C-24), 70.3 (C-1), 46.2 (C-8), 
38.3 (C-6), 27.1 (C-10 and C-11). 
 
4.2.15 Synthesis of 3-((4R,5R)-5-(Benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-3-
phenylpropanoic acid 101   
 
Methyl 3-((4R,5R)-5-(benzyloxymethyl)-2,2-dimethyl-1,3-
dioxolan-4-yl)-3-phenylpropanoate 100 (0.300 g, 0.78 mmol) 
was dissolved in MeOH (10 cm3). 5% aqueous KOH solution 
(20 cm3) was added to the reaction mixture. The reaction 
mixture was stirred for 18 h at room temperature. The organic 
solvent was removed in vacuo. Saturated aqueous NaHCO3 
solution (50 cm3) was added to the pale yellow residue and washed with Et2O (50 cm3). 
The aqueous extract was collected and cooled to 0 °C. 5% aqueous HCl solution was 
carefully added to the aqueous extract until the mixture was slightly acidic – pH was 
monitored using pH indicator paper. The desired carboxylic acid (0.230 g, 80%) was 
extracted with EtOAc (3 × 50 cm3) and dried with Na2SO4 and the solvent removed in 
vacuo. [α]25D + 38.3 MeOH, c = 5 mg.ml-1); Rf = 0 (20% EtOAc/hexane); IR : νmax(cm-1) 
= 3219 (s, b, OH), 1725 (s, C=O); 1H NMR (300 MHz, CDCl3): δH = ≈ 9.00 (1H, s, 21-
OH), 7.13 – 7.32 (10H, m, 10 × A-H’s), 4.27 (2H, s, 22-CH2), 3.87 – 3.96 (2H, m, 1-
CH2), 3.22 (1H, dt, J = 9.3, 8.9, 5.5 Hz, 5-CH), 3.09 (1H, dd, J = 15.9, 3.5 Hz, 4-CH), 
2.68 (1H, dd, J = 15.9, 10.4 Hz, 6-CH), 1.41 (6H, d, J = 3.7 Hz, 10-CH3 and 11-CH3); 13C 
NMR (75 MHz, CDCl3) δC = 178.9 (C-12), 140.2 (C-15), 139.1 (C-23), 129.8 (C-17 and 
C-19), 129.4 (C-18), 129.2 (C-16 and C-20), 128.7 (C-25 and C-27), 128.7 (C-26), 128.6 
(C-24 and C-28), 110.4 (C-9), 81.2 (C-5), 81.1 (C-4), 74.3 (C-22), 71.3 (C-1), 47.7 (C-8), 
39.3 (C-6), 28.3 (C-10 and C-11). 
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4.2.16 Attempted Synthesis of Ring Closed Compound 78 
 
All glassware was flame dried and anhydrous  
solvents used. 3-(Benzo[d][1,3]dioxol-5-yl)-3-((4R,5R)-5-
(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)propanoic 
acid 76 (0.550 g, 1.3 mmol) was dissolved in toluene (20 
cm3). The solution was cooled to 0 °C before DPPA (0.411 g, 
0.3 cm3, 1.5 mmol, 1.1 equiv) and triethyl amine (0.268 g, 0.4 
cm3, 2.6 mmol, 2 equiv) was added. The presence of gas 
bubbles indicated that N2 gas was being evolved and hence the formation of the 
isocyanate intermediate The reaction mixture was stirred at 0 °C for 10 min. At this point 
an IR was run to determine if the isocyanate had indeed formed.  
IR : νmax(cm-1) = 2166 (m, NCO) 
 
The reaction mixture was then allowed to warm to room temperature and subsequently 
heated to 110 °C. The reaction mixture was heated at reflux for 24 h. The reaction 
mixture was cooled to room temperature and the toluene removed in vacuo. The residue 
was washed with 0.1 N aqueous NaOH solution (50 cm3) and extracted with EtOAc (3 × 
50 cm3). The extracts were dried over Na2SO4 and the solvent removed in vacuo. The 
unknown compound (0.200 g), an opaque gum, was purified by silica gel column 
chromatography (20% EtOAc/hexane). [α]25D + 81.9 (EtOAc, c = 14 mg.ml-1); Rf = 35 
(20% EtOAc/hexane); 1H NMR (300 MHz, CDCl3): δH = 7.28-6.61 (8 × Aromatic 
protons), 5.87 (1H, m, 19-CH2), 5.85 (1H, m, 19-CH2), 5.47 (1H, t, J = 5.3, 5.3 Hz, 20-
NH), 4.35 (2H, s, 24-CH2), 3.99 (1H, m, 5-CH), 3.90 (1H, ddd, J = 7.9, 5.5, 2.76 Hz, 4-
CH),  3.75 (1H, ddd, J = 13.6, 6.9, 5.6 Hz, 6-CH), 3.46 (1H, ddd, J = 13.7, 7.4, 6.36 Hz, 
8-CH2), 2.98 (1H, dd, J = 10.6, 2.8 Hz, 1-CH2), 2.90 (1H, dd, J= 10.6, 5.5 Hz, 1-CH2), 
2.81 (1H, m, 8-CH2), 1.45 (3H, s, 23-CH3), 1.43 (3H, s, 10-CH3); 13C NMR (75 MHz, 
CDCl3) δC = 156.13 (Unknown), 148.09 (C-14), 147.10 (C-13), 137.81 (C-25), 131.26 
(C-11), 128.25 (C-27 and C-29), 127.54 (C-28, C-26 and C-30), 121.42 (C-16), 109.52 
1
O
O4
5
6
O
8
9 10
11
1213
14
15
16
O
17
O
18
19
NH
2021
23
24
25
26
2728
29
30
O
  
82 
(C-15), 108.67 (C-12), 107.94 (C-9), 101.14 (C-3), 80.09 (C-5), 79.96 (C-4), 73.26 (C-
24), 70.03 (C-1), 49.38 (C-8), 44.70 (C-6), 27.22 (C-10 or C-23), 27.04 (C-10 or C-23)  
4.2.18 Synthesis of Methyl 3,3-diphenylpropanoate 93 
 
Magnesium turnings (0.763 g, 31.4 mmol, 10 equiv.) were added 
to anhydrous THF (15 cm3). Phenyl bromide (3.3 cm3, 4.84 g, 
30.8 mmol, 10 equiv.), dissolved in anhydrous THF (5 cm3) was 
then added. The reaction mixture was subsequently left to stand 
without stirring for approximately 20 min. Stirring only started 
when heat was generated by the reaction mixture. The reaction was stirred for 
approximately 30 min. or until the reaction mixture cooled down, indicating the reaction 
was complete. In a separate vessel copper (I) iodide (2.68 g, 14.1 mmol, 5 equiv.) was 
added to anhydrous THF (15 cm3) and cooled to -65 °C. The Grignard, previously 
prepared, was then cannulated to the cooled copper (I) iodide/THF mixture. The reaction 
mixture was stirred for one h at -60 °C. Methyl cinnamate (0.5 g, 3.1 mmol) was 
dissolved in anhydrous THF (15 cm3) and cannulated to the organocopper reagent 
mixture. The reaction mixture was warmed slowly to room temperature and stirred for 20 
h. The reaction mixture was quenched with saturated aqueous NH4Cl solution (3 × 50 
cm3) followed by the extraction of organic components using EtOAc (3 × 50 cm3). The 
organic extracts were combined and dried with Na2SO4 and the solvent removed in 
vacuo. The product (0.350 g, 47%) was isolated using silica gel column chromatography 
(20% EtOAc/hexane) as a clear oil. Rf = 0.15 (20% EtOAc/Hexane); 1H NMR (300 
MHz, CDCl3): δH = 7.14 – 7.29 (10H, m, 10 × A-H’s), 4.55 (1H, t, J = 8.0 Hz, 7-CH), 
3.55 (3H, s, 18-CH3), 3.06 (2H, d, J = 8.0 Hz, 8-CH2). 
 
4.2.19 Synthesis of Methyl 3-(4-methoxyphenyl)-3-phenylpropanoate 94 
 
Magnesium turnings (0.755 g, 31.0 mmol, 10 equiv.) was added 
to anhydrous THF (15 cm3). 1-Bromo anisole (3.85 cm3, 5.76 g, 
30.8 mmol, 10 equiv.) dissolved in anhydrous THF (15 cm3) was 
then added. The reaction mixture was subsequently left to stand 
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without stirring for approximately 20 min. Stirring was only started when heat was 
generated by the reaction mixture. The reaction was stirred for approximately 30 min. or 
until the reaction mixture cooled down, indicating the reaction was complete. In a 
separate vessel copper (I) iodide (2.96 g, 15.5 mmol, 5 equiv.) was added to anhydrous 
THF (15 cm3) and cooled to -65 °C. The Grignard, previously prepared, was then 
cannulated to the cooled copper (I) iodide/THF mixture. The reaction mixture was 
subsequently stirred for 1 h at -60 °C. Methyl cinnamate (0.5 g, 3.1 mmol) was dissolved 
in anhydrous THF (15 cm3) and cannulated to the organocopper reagent mixture. The 
reaction mixture was warmed slowly to room temperature and stirred for 20 h. The 
reaction mixture was quenched with the addition of saturated aqueous NH4Cl solution (3 
× 50 cm3) and the organic components extracted with EtOAc (3 × 50 cm3). The organic 
extracts were combined and dried with Na2SO4 and the solvent removed in vacuo. The 
product 76 (0.230 mg, 28%) was isolated as a clear oil using silica gel column 
chromatography (20% EtOAc/hexane). The desired product was purified further by re-
crystallisation using EtOAc. Rf = 0.5 (20% EtOAc/hexane); 1H NMR (300 MHz, 
CDCl3): δH = 7.12 – 7.29 (9H, m, 9 × A-H’s), 4.50 (1H, t, J = 7.99 Hz, 7-CH), 3.75 (3H, 
s, 22-CH3), 3.56 (3H, s, 18-CH3), 3.02 (2H, d, J = 8.0 Hz, 8-CH2). 
 
4.2.20 Synthesis of Methyl 3-(3,4-dimethoxyphenyl)-3-phenylpropanoate 95  
 
Magnesium turnings (0.750 g, 30.8 mmol, 10 equiv.) was added 
to anhydrous THF (15 cm3). 4-bromo veratrole (4.47 cm3, 6.7 g, 
30.7 mmol, 10 equiv.) dissolved in anhydrous THF (15 cm3) 
was then added. The reaction mixture was subsequently left to 
stand without stirring for approximately 20 min. Stirring was 
only started when heat was generated by the reaction mixture. 
The reaction was stirred for approximately 30 min. or until the reaction mixture cooled 
down, indicating the reaction was complete. In a separate vessel copper (I) iodide (2.93 g, 
15.4 mmol, 5 equiv.) was mixed with anhydrous THF (15 cm3) and cooled to -65 °C. The 
Grignard, prepared previously, was then cannulated to the cooled copper (I) iodide/THF 
mixture. The reaction mixture was stirred for 1 h at -60 °C. Methyl cinnamate (0.5g, 3.1 
14
8
9
10
11
12 15
7
16
4
21
17
13
5
18
O
OMe 6
O
O
2
3
  
84 
mmol) was dissolved in anhydrous THF (15 cm3) and cannulated to the organocopper 
reagent mixture. The reaction mixture was warmed slowly to room temperature and 
stirred for 20 h. The reaction was quenched with saturated aqueous NH4Cl solution (3 × 
50 cm3) and the organic products extracted with EtOAc (3 × 50 cm3). The organic 
extracts were combined and dried with Na2SO4 and the solvent removed in vacuo. The 
addition ester product, methyl 3-(3,4-dimethoxyphenyl)-3-phenylpropanoate, (320 mg, 
46%) was isolated with impurities with  using silica gel column chromatography. Despite 
several re-purification attempts, a clean spectrum was not obtained and it was decided to 
use the impure product in the next reaction. 
 
4.2.21 Synthesis of 3-(3,4-Dimethoxyphenyl)-3-phenylpropanoic acid 96 
 
A mixture of Methyl 3-(3,4-dimethoxyphenyl)-3-
phenylpropanoate (0.320 g, 1.1 mmol) 95, 5% aqueous NaOH 
solution (15 cm3) and MeOH (25 cm3) was heated at reflux for 
2.5 h. The solvent was subsequently removed in vacuo. The 
residue was then washed with distilled water (25 cm3) and 
extracted with Et2O (3 × 50 cm3). The desired compound 79 
was purified using column chromatography (40% EtOAc/Hexane) as clear crystals (0.060 
g, 6.8%).  Rf = 0.27 (40% EtOAc/hexane); 1H NMR (300 MHz, CDCl3): δH = 9.54 (1H, 
bs, 6-OH), 7.17 – 7.29 (5H, m, 5 × A-H’s), 6.71 – 6.77 (3H, m, 4-CH, 5-CH and 21-CH), 
4.47 (1H, t, J = 7.9 Hz, 15-CH), 3.81 (3H, s, 2-CH3 or 3-CH3), 3.79 (3H, s, 2-CH3 or 3-
CH3), 3.04 (2H, d, J = 7.9 Hz, 7-CH2). 
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Appendix  
 
A1.1: 1H and 13C NMR spectra for compounds successfully synthesised 
 
A1.1.1 1H NMR spectrum of 82 
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A1.1.2 13C NMR spectrum of 82 
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A1.2.1 1H NMR spectrum of 83 
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A1.3.1 1H NMR spectrum of 84 
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A1.4.1 1H NMR spectrum of 85 
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A1.7.1 1H NMR spectrum of 70 
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A1.8.1 1H NMR spectrum of 71 
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A1.9.1 1H NMR spectrum of 72 
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A1.10.1 1H NMR spectrum of 73 
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A1.10.2 13C NMR spectrum of 73 
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A1.20.1 1H NMR spectrum of 94 
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A1.21.1 1H NMR spectrum of 96 
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A2.1: Single crystal data and structure for 3-((4R,5R)-5-(benzyloxymethyl)-2,2-dimethyl-
1,3-dioxolan-4-yl)-3-phenylpropanoic acid 101 
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Table A2.1.1 Crystal data and structure refinement for 101 
 
Identification code  101 
Empirical formula  C10 H10 N O 
Formula weight  160.19 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 5.9680(6) Å = 90°. 
 b = 20.466(2) Å = 97.854(4)°. 
 c = 16.2314(18) Å  = 90°. 
Volume 1963.9(4) Å3 
Z 3 
Density (calculated) 0.406 Mg/m3 
Absorption coefficient 0.026 mm-1 
F(000) 255 
Crystal size 0.32 x 0.07 x 0.07 mm3 
Theta range for data collection 1.27 to 25.00°. 
Index ranges -7<=h<=6, -24<=k<=24, -19<=l<=14 
Reflections collected 12158 
Independent reflections 6885 [R(int) = 0.0647] 
  
104 
Completeness to theta = 25.00° 99.8 %  
Max. and min. transmission 0.9981 and 0.9916 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6885 / 1 / 487 
Goodness-of-fit on F2 0.932 
Final R indices [I>2sigma(I)] R1 = 0.0601, wR2 = 0.0721 
R indices (all data) R1 = 0.1238, wR2 = 0.0877 
Absolute structure parameter 0.1(10) 
Largest diff. peak and hole 0.195 and -0.185 e.Å-3 
 
Table A2.1.2  Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for 101. U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
________________________________________________________________________
________ 
 x y z U(eq) 
________________________________________________________________________
________ 
C(96) 857(6) 908(2) 1145(2) 31(1) 
C(95) 4748(6) 1414(2) 1320(2) 34(1) 
C(97) -7056(7) 1030(2) -4412(2) 41(1) 
C(98) -10368(6) 1165(2) -3619(3) 45(1) 
O(4) 1975(4) 1671(1) 2234(2) 28(1) 
O(9) -60(4) 3322(1) 382(2) 29(1) 
O(7) -2387(4) 1978(1) -260(2) 39(1) 
O(1) -8713(4) 2078(1) -4241(2) 29(1) 
O(10) -9218(4) 3387(1) -4645(2) 31(1) 
O(3) 1335(4) 2044(1) 918(2) 26(1) 
O(2) -6677(4) 1593(1) -3119(2) 28(1) 
O(6) 8415(4) 2460(2) 3769(2) 42(1) 
C(009) 4060(6) 3353(2) 2930(2) 24(1) 
O(5) 7022(4) 2242(1) 4938(2) 38(1) 
C(011) -7492(6) 2581(2) -3742(2) 20(1) 
O(8) -640(4) 2240(1) -1341(2) 37(1) 
C(013) -132(6) 3093(2) 1204(2) 25(1) 
C(014) 4093(6) 2616(2) 2871(2) 22(1) 
  
105 
C(015) 1963(6) 2365(2) 2321(2) 22(1) 
C(016) 1775(6) 2616(2) 1416(2) 20(1) 
C(017) -4632(6) 2028(2) -1554(2) 31(1) 
C(018) -5285(6) 3191(2) -2063(2) 22(1) 
C(019) 4425(6) 2287(2) 3724(2) 26(1) 
C(020) 2265(6) 1502(2) 1409(2) 25(1) 
C(021) 2379(7) 3673(2) 3285(2) 32(1) 
C(022) -2345(7) 2107(2) -1053(2) 25(1) 
C(023) 5669(7) 3728(2) 2618(2) 32(1) 
C(024) -4994(6) 2484(2) -2308(2) 28(1) 
C(025) 3961(7) 4715(2) 3006(3) 40(1) 
C(026) -10860(7) 3895(2) -4801(2) 32(1) 
C(027) -10157(7) 4528(2) -4367(2) 29(1) 
C(028) 2332(7) 4346(2) 3323(3) 38(1) 
C(029) -1929(7) 3731(2) 100(2) 35(1) 
C(030) -8953(7) 3182(2) -3806(2) 29(1) 
C(031) -7031(7) 3381(2) -1626(2) 35(1) 
C(032) -1825(7) 4397(2) 492(2) 26(1) 
C(033) -3757(7) 4782(2) 428(2) 33(1) 
C(034) 6822(7) 2346(2) 4130(3) 29(1) 
C(035) 230(7) 5279(2) 1228(3) 36(1) 
C(036) -8214(7) 1458(2) -3845(2) 27(1) 
C(037) -5980(8) 4498(2) -1709(3) 48(1) 
C(038) 167(7) 4661(2) 894(3) 36(1) 
C(039) -7060(6) 2254(2) -2897(2) 23(1) 
C(040) -3879(8) 3669(2) -2299(2) 38(1) 
C(041) -11509(7) 4827(2) -3865(2) 31(1) 
C(042) -3699(7) 5401(2) 758(2) 36(1) 
C(043) -7375(7) 4031(2) -1455(3) 42(1) 
C(044) 5635(8) 4403(2) 2663(3) 39(1) 
C(045) -7458(8) 5401(2) -4053(3) 44(1) 
C(046) -8096(7) 4817(2) -4452(3) 38(1) 
C(047) -1695(7) 5655(2) 1164(3) 40(1) 
C(048) -8879(8) 5695(2) -3556(3) 43(1) 
C(049) -10908(8) 5410(2) -3464(3) 37(1) 
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C(050) -4243(9) 4320(2) -2125(3) 47(1) 
 
Table A2.1.3 Bond lengths [Å] and angles [°] for 101  
 
C(96)-C(020)  1.507(5) 
C(96)-H(96A)  0.9800 
C(96)-H(96B)  0.9800 
C(96)-H(96C)  0.9800 
C(95)-C(020)  1.519(5) 
C(95)-H(95A)  0.9800 
C(95)-H(95B)  0.9800 
C(95)-H(95C)  0.9800 
C(97)-C(036)  1.505(5) 
C(97)-H(97A)  0.9800 
C(97)-H(97B)  0.9800 
C(97)-H(97C)  0.9800 
C(98)-C(036)  1.508(5) 
C(98)-H(98A)  0.9800 
C(98)-H(98B)  0.9800 
C(98)-H(98C)  0.9800 
O(4)-C(020)  1.415(4) 
O(4)-C(015)  1.429(4) 
O(9)-C(013)  1.420(4) 
O(9)-C(029)  1.420(4) 
O(7)-C(022)  1.317(4) 
O(7)-H(7)  0.8400 
O(1)-C(036)  1.436(4) 
O(1)-C(011)  1.443(4) 
O(10)-C(030)  1.413(4) 
O(10)-C(026)  1.427(4) 
O(3)-C(016)  1.427(4) 
O(3)-C(020)  1.432(4) 
O(2)-C(036)  1.418(4) 
O(2)-C(039)  1.427(4) 
O(6)-C(034)  1.205(4) 
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C(009)-C(023)  1.380(5) 
C(009)-C(021)  1.388(5) 
C(009)-C(014)  1.511(5) 
O(5)-C(034)  1.319(4) 
O(5)-H(5)  0.8400 
C(011)-C(030)  1.503(5) 
C(011)-C(039)  1.517(5) 
C(011)-H(011)  1.0000 
O(8)-C(022)  1.208(4) 
C(013)-C(016)  1.503(5) 
C(013)-H(01A)  0.9900 
C(013)-H(01B)  0.9900 
C(014)-C(019)  1.527(5) 
C(014)-C(015)  1.538(5) 
C(014)-H(014)  1.0000 
C(015)-C(016)  1.545(5) 
C(015)-H(015)  1.0000 
C(016)-H(016)  1.0000 
C(017)-C(022)  1.499(5) 
C(017)-C(024)  1.532(5) 
C(017)-H(01C)  0.9900 
C(017)-H(01D)  0.9900 
C(018)-C(040)  1.377(5) 
C(018)-C(031)  1.394(5) 
C(018)-C(024)  1.516(5) 
C(019)-C(034)  1.496(5) 
C(019)-H(01E)  0.9900 
C(019)-H(01F)  0.9900 
C(021)-C(028)  1.379(5) 
C(021)-H(021)  0.9500 
C(023)-C(044)  1.383(5) 
C(023)-H(023)  0.9500 
C(024)-C(039)  1.527(5) 
C(024)-H(024)  1.0000 
C(025)-C(044)  1.366(5) 
C(025)-C(028)  1.384(6) 
  
108 
C(025)-H(025)  0.9500 
C(026)-C(027)  1.507(5) 
C(026)-H(02A)  0.9900 
C(026)-H(02B)  0.9900 
C(027)-C(041)  1.367(5) 
C(027)-C(046)  1.389(5) 
C(028)-H(028)  0.9500 
C(029)-C(032)  1.502(5) 
C(029)-H(02C)  0.9900 
C(029)-H(02D)  0.9900 
C(030)-H(03A)  0.9900 
C(030)-H(03B)  0.9900 
C(031)-C(043)  1.380(6) 
C(031)-H(031)  0.9500 
C(032)-C(038)  1.385(5) 
C(032)-C(033)  1.389(5) 
C(033)-C(042)  1.373(5) 
C(033)-H(033)  0.9500 
C(035)-C(038)  1.374(5) 
C(035)-C(047)  1.375(5) 
C(035)-H(035)  0.9500 
C(037)-C(050)  1.362(6) 
C(037)-C(043)  1.367(6) 
C(037)-H(037)  0.9500 
C(038)-H(038)  0.9500 
C(039)-H(039)  1.0000 
C(040)-C(050)  1.385(5) 
C(040)-H(040)  0.9500 
C(041)-C(049)  1.382(5) 
C(041)-H(041)  0.9500 
C(042)-C(047)  1.386(5) 
C(042)-H(042)  0.9500 
C(043)-H(043)  0.9500 
C(044)-H(044)  0.9500 
C(045)-C(048)  1.386(5) 
C(045)-C(046)  1.388(6) 
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C(045)-H(045)  0.9500 
C(046)-H(046)  0.9500 
C(047)-H(047)  0.9500 
C(048)-C(049)  1.371(5) 
C(048)-H(048)  0.9500 
C(049)-H(049)  0.9500 
C(050)-H(050)  0.9500 
 
C(020)-C(96)-H(96A) 109.5 
C(020)-C(96)-H(96B) 109.5 
H(96A)-C(96)-H(96B) 109.5 
C(020)-C(96)-H(96C) 109.5 
H(96A)-C(96)-H(96C) 109.5 
H(96B)-C(96)-H(96C) 109.5 
C(020)-C(95)-H(95A) 109.5 
C(020)-C(95)-H(95B) 109.5 
H(95A)-C(95)-H(95B) 109.5 
C(020)-C(95)-H(95C) 109.5 
H(95A)-C(95)-H(95C) 109.5 
H(95B)-C(95)-H(95C) 109.5 
C(036)-C(97)-H(97A) 109.5 
C(036)-C(97)-H(97B) 109.5 
H(97A)-C(97)-H(97B) 109.5 
C(036)-C(97)-H(97C) 109.5 
H(97A)-C(97)-H(97C) 109.5 
H(97B)-C(97)-H(97C) 109.5 
C(036)-C(98)-H(98A) 109.5 
C(036)-C(98)-H(98B) 109.5 
H(98A)-C(98)-H(98B) 109.5 
C(036)-C(98)-H(98C) 109.5 
H(98A)-C(98)-H(98C) 109.5 
H(98B)-C(98)-H(98C) 109.5 
C(020)-O(4)-C(015) 109.8(3) 
C(013)-O(9)-C(029) 111.9(3) 
C(022)-O(7)-H(7) 109.5 
C(036)-O(1)-C(011) 108.8(3) 
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C(030)-O(10)-C(026) 111.8(3) 
C(016)-O(3)-C(020) 107.0(3) 
C(036)-O(2)-C(039) 106.7(3) 
C(023)-C(009)-C(021) 117.9(4) 
C(023)-C(009)-C(014) 121.1(4) 
C(021)-C(009)-C(014) 121.0(4) 
C(034)-O(5)-H(5) 109.5 
O(1)-C(011)-C(030) 107.5(3) 
O(1)-C(011)-C(039) 101.7(3) 
C(030)-C(011)-C(039) 116.7(3) 
O(1)-C(011)-H(011) 110.2 
C(030)-C(011)-H(011) 110.2 
C(039)-C(011)-H(011) 110.2 
O(9)-C(013)-C(016) 108.0(3) 
O(9)-C(013)-H(01A) 110.1 
C(016)-C(013)-H(01A) 110.1 
O(9)-C(013)-H(01B) 110.1 
C(016)-C(013)-H(01B) 110.1 
H(01A)-C(013)-H(01B) 108.4 
C(009)-C(014)-C(019) 112.5(3) 
C(009)-C(014)-C(015) 110.6(3) 
C(019)-C(014)-C(015) 112.0(3) 
C(009)-C(014)-H(014) 107.1 
C(019)-C(014)-H(014) 107.1 
C(015)-C(014)-H(014) 107.1 
O(4)-C(015)-C(014) 112.0(3) 
O(4)-C(015)-C(016) 103.7(3) 
C(014)-C(015)-C(016) 112.8(3) 
O(4)-C(015)-H(015) 109.4 
C(014)-C(015)-H(015) 109.4 
C(016)-C(015)-H(015) 109.4 
O(3)-C(016)-C(013) 109.2(3) 
O(3)-C(016)-C(015) 104.4(3) 
C(013)-C(016)-C(015) 112.8(3) 
O(3)-C(016)-H(016) 110.1 
C(013)-C(016)-H(016) 110.1 
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C(015)-C(016)-H(016) 110.1 
C(022)-C(017)-C(024) 112.8(3) 
C(022)-C(017)-H(01C) 109.0 
C(024)-C(017)-H(01C) 109.0 
C(022)-C(017)-H(01D) 109.0 
C(024)-C(017)-H(01D) 109.0 
H(01C)-C(017)-H(01D) 107.8 
C(040)-C(018)-C(031) 117.9(4) 
C(040)-C(018)-C(024) 120.6(4) 
C(031)-C(018)-C(024) 121.4(4) 
C(034)-C(019)-C(014) 111.2(3) 
C(034)-C(019)-H(01E) 109.4 
C(014)-C(019)-H(01E) 109.4 
C(034)-C(019)-H(01F) 109.4 
C(014)-C(019)-H(01F) 109.4 
H(01E)-C(019)-H(01F) 108.0 
O(4)-C(020)-O(3) 104.5(3) 
O(4)-C(020)-C(96) 109.3(3) 
O(3)-C(020)-C(96) 107.9(3) 
O(4)-C(020)-C(95) 111.5(3) 
O(3)-C(020)-C(95) 110.4(3) 
C(96)-C(020)-C(95) 112.9(3) 
C(028)-C(021)-C(009) 120.7(4) 
C(028)-C(021)-H(021) 119.6 
C(009)-C(021)-H(021) 119.6 
O(8)-C(022)-O(7) 123.6(3) 
O(8)-C(022)-C(017) 124.5(4) 
O(7)-C(022)-C(017) 111.8(3) 
C(009)-C(023)-C(044) 121.4(4) 
C(009)-C(023)-H(023) 119.3 
C(044)-C(023)-H(023) 119.3 
C(018)-C(024)-C(039) 110.3(3) 
C(018)-C(024)-C(017) 112.3(3) 
C(039)-C(024)-C(017) 109.0(3) 
C(018)-C(024)-H(024) 108.4 
C(039)-C(024)-H(024) 108.4 
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C(017)-C(024)-H(024) 108.4 
C(044)-C(025)-C(028) 119.1(4) 
C(044)-C(025)-H(025) 120.4 
C(028)-C(025)-H(025) 120.4 
O(10)-C(026)-C(027) 113.7(3) 
O(10)-C(026)-H(02A) 108.8 
C(027)-C(026)-H(02A) 108.8 
O(10)-C(026)-H(02B) 108.8 
C(027)-C(026)-H(02B) 108.8 
H(02A)-C(026)-H(02B) 107.7 
C(041)-C(027)-C(046) 118.1(4) 
C(041)-C(027)-C(026) 121.0(4) 
C(046)-C(027)-C(026) 120.9(4) 
C(021)-C(028)-C(025) 120.5(5) 
C(021)-C(028)-H(028) 119.7 
C(025)-C(028)-H(028) 119.7 
O(9)-C(029)-C(032) 114.4(3) 
O(9)-C(029)-H(02C) 108.6 
C(032)-C(029)-H(02C) 108.6 
O(9)-C(029)-H(02D) 108.6 
C(032)-C(029)-H(02D) 108.6 
H(02C)-C(029)-H(02D) 107.6 
O(10)-C(030)-C(011) 107.3(3) 
O(10)-C(030)-H(03A) 110.3 
C(011)-C(030)-H(03A) 110.3 
O(10)-C(030)-H(03B) 110.3 
C(011)-C(030)-H(03B) 110.3 
H(03A)-C(030)-H(03B) 108.5 
C(043)-C(031)-C(018) 121.0(4) 
C(043)-C(031)-H(031) 119.5 
C(018)-C(031)-H(031) 119.5 
C(038)-C(032)-C(033) 117.7(4) 
C(038)-C(032)-C(029) 122.4(4) 
C(033)-C(032)-C(029) 119.8(4) 
C(042)-C(033)-C(032) 121.2(4) 
C(042)-C(033)-H(033) 119.4 
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C(032)-C(033)-H(033) 119.4 
O(6)-C(034)-O(5) 123.0(4) 
O(6)-C(034)-C(019) 124.9(4) 
O(5)-C(034)-C(019) 112.1(4) 
C(038)-C(035)-C(047) 120.5(4) 
C(038)-C(035)-H(035) 119.7 
C(047)-C(035)-H(035) 119.7 
O(2)-C(036)-O(1) 105.7(3) 
O(2)-C(036)-C(97) 108.8(3) 
O(1)-C(036)-C(97) 109.0(3) 
O(2)-C(036)-C(98) 110.5(3) 
O(1)-C(036)-C(98) 109.2(3) 
C(97)-C(036)-C(98) 113.3(4) 
C(050)-C(037)-C(043) 120.0(5) 
C(050)-C(037)-H(037) 120.0 
C(043)-C(037)-H(037) 120.0 
C(035)-C(038)-C(032) 121.3(4) 
C(035)-C(038)-H(038) 119.4 
C(032)-C(038)-H(038) 119.4 
O(2)-C(039)-C(011) 101.7(3) 
O(2)-C(039)-C(024) 108.0(3) 
C(011)-C(039)-C(024) 116.9(3) 
O(2)-C(039)-H(039) 109.9 
C(011)-C(039)-H(039) 109.9 
C(024)-C(039)-H(039) 109.9 
C(018)-C(040)-C(050) 120.6(5) 
C(018)-C(040)-H(040) 119.7 
C(050)-C(040)-H(040) 119.7 
C(027)-C(041)-C(049) 122.1(4) 
C(027)-C(041)-H(041) 119.0 
C(049)-C(041)-H(041) 119.0 
C(033)-C(042)-C(047) 120.4(4) 
C(033)-C(042)-H(042) 119.8 
C(047)-C(042)-H(042) 119.8 
C(037)-C(043)-C(031) 119.9(5) 
C(037)-C(043)-H(043) 120.0 
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C(031)-C(043)-H(043) 120.0 
C(025)-C(044)-C(023) 120.3(5) 
C(025)-C(044)-H(044) 119.8 
C(023)-C(044)-H(044) 119.8 
C(048)-C(045)-C(046) 119.7(4) 
C(048)-C(045)-H(045) 120.1 
C(046)-C(045)-H(045) 120.1 
C(045)-C(046)-C(027) 120.7(4) 
C(045)-C(046)-H(046) 119.7 
C(027)-C(046)-H(046) 119.7 
C(035)-C(047)-C(042) 118.9(4) 
C(035)-C(047)-H(047) 120.5 
C(042)-C(047)-H(047) 120.5 
C(049)-C(048)-C(045) 119.9(4) 
C(049)-C(048)-H(048) 120.1 
C(045)-C(048)-H(048) 120.1 
C(048)-C(049)-C(041) 119.5(4) 
C(048)-C(049)-H(049) 120.3 
C(041)-C(049)-H(049) 120.3 
C(037)-C(050)-C(040) 120.5(5) 
C(037)-C(050)-H(050) 119.7 
C(040)-C(050)-H(050) 119.7 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table A2.1.4 Anisotropic displacement parameters (Å2x 103)for 101. The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
________________________________________________________________________
______ 
 U11 U22 U33 U23 U13 U12 
________________________________________________________________________
______ 
C(96) 35(3)  25(3) 30(3)  -2(2) -3(2)  2(2) 
C(95) 30(3)  34(3) 37(3)  -8(2) 0(2)  7(2) 
C(97) 41(3)  42(3) 36(3)  -15(2) -7(2)  7(2) 
C(98) 39(3)  43(3) 49(3)  3(3) -6(3)  -12(3) 
O(4) 39(2)  25(2) 18(2)  0(1) 2(1)  0(2) 
O(9) 36(2)  30(2) 20(2)  5(2) 4(1)  15(2) 
O(7) 33(2)  60(2) 21(2)  9(2) -4(1)  -4(2) 
O(1) 35(2)  21(2) 27(2)  -2(1) -12(1)  0(1) 
O(10) 48(2)  25(2) 18(2)  1(1) -3(1)  10(2) 
O(3) 31(2)  25(2) 21(2)  -2(1) -3(1)  3(1) 
O(2) 33(2)  18(2) 29(2)  0(1) -9(1)  -5(1) 
O(6) 28(2)  64(2) 35(2)  -1(2) 8(2)  -1(2) 
C(009) 20(2)  32(3) 19(2)  -1(2) 0(2)  -1(2) 
O(5) 29(2)  58(2) 23(2)  4(2) -7(1)  -6(2) 
C(011) 22(2)  19(2) 18(2)  -3(2) -1(2)  1(2) 
O(8) 25(2)  54(2) 31(2)  3(2) 1(1)  -8(2) 
C(013) 30(3)  25(3) 19(2)  3(2) 2(2)  2(2) 
C(014) 18(2)  26(2) 22(2)  -1(2) 6(2)  1(2) 
C(015) 25(2)  19(2) 23(2)  -3(2) 6(2)  4(2) 
C(016) 16(2)  24(3) 20(3)  0(2) 3(2)  0(2) 
C(017) 34(2)  28(3) 27(2)  7(2) -9(2)  -4(2) 
C(018) 24(2)  23(2) 18(2)  -1(2) -2(2)  -4(2) 
C(019) 26(2)  27(3) 25(2)  0(2) 0(2)  -4(2) 
C(020) 28(3)  25(3) 19(3)  -2(2) -3(2)  7(2) 
C(021) 33(3)  33(3) 31(3)  -4(2) 5(2)  -2(2) 
C(022) 32(3)  19(2) 21(3)  2(2) -3(2)  -1(2) 
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C(023) 31(3)  42(3) 26(3)  -3(2) 8(2)  -2(2) 
C(024) 29(2)  31(3) 22(3)  4(2) 0(2)  -9(2) 
C(025) 48(3)  22(3) 46(3)  -3(2) -6(3)  3(3) 
C(026) 40(3)  26(3) 27(3)  4(2) -7(2)  8(2) 
C(027) 34(3)  26(3) 24(3)  3(2) -4(2)  6(2) 
C(028) 39(3)  40(3) 34(3)  -12(2) 3(2)  6(3) 
C(029) 41(3)  33(3) 27(3)  5(2) -5(2)  13(2) 
C(030) 43(3)  23(3) 20(2)  -1(2) 0(2)  1(2) 
C(031) 38(3)  35(3) 31(3)  -5(2) 5(2)  -8(2) 
C(032) 30(3)  29(3) 20(2)  7(2) 6(2)  2(2) 
C(033) 24(3)  36(3) 35(3)  4(2) -2(2)  5(2) 
C(034) 37(3)  23(3) 24(3)  -3(2) -6(2)  1(2) 
C(035) 33(3)  30(3) 45(3)  2(2) 2(2)  -6(2) 
C(036) 27(3)  26(3) 25(3)  -1(2) -8(2)  2(2) 
C(037) 83(4)  29(3) 32(3)  -10(2) 10(3)  -6(3) 
C(038) 29(3)  34(3) 43(3)  8(2) 5(2)  7(2) 
C(039) 28(2)  18(2) 20(2)  -1(2) -1(2)  -3(2) 
C(040) 58(3)  39(3) 21(3)  -7(2) 15(2)  -17(3) 
C(041) 41(3)  22(3) 30(3)  2(2) 7(2)  0(2) 
C(042) 35(3)  38(3) 38(3)  5(2) 13(2)  9(2) 
C(043) 31(3)  45(3) 49(3)  -13(3) 4(2)  -1(3) 
C(044) 44(3)  34(3) 36(3)  1(3) -2(2)  -16(3) 
C(045) 41(3)  45(3) 43(3)  3(3) -2(3)  -7(3) 
C(046) 34(3)  43(3) 37(3)  1(3) 3(2)  8(3) 
C(047) 52(3)  26(3) 44(3)  1(2) 14(3)  3(3) 
C(048) 70(4)  25(3) 32(3)  0(2) -5(3)  -2(3) 
C(049) 55(3)  32(3) 26(3)  0(2) 12(2)  5(3) 
C(050) 87(4)  27(3) 28(3)  -4(2) 13(3)  -20(3) 
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Table A2.1.5 Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 
103) for 101. 
________________________________________________________________________
________ 
 x  y  z  U(eq) 
________________________________________________________________________
________ 
 
H(96A) 1050 791 574 46 
H(96B) -740 1004 1173 46 
H(96C) 1344 543 1517 46 
H(95A) 4890 1298 743 52 
H(95B) 5391 1064 1692 52 
H(95C) 5563 1822 1466 52 
H(97A) -8107 932 -4915 61 
H(97B) -6578 621 -4125 61 
H(97C) -5729 1257 -4565 61 
H(98A) -11406 1072 -4127 67 
H(98B) -11078 1473 -3273 67 
H(98C) -10018 758 -3310 67 
H(7) -1084 2025 3 58 
H(5) 8386 2279 5145 56 
H(011) -6027 2675 -3952 24 
H(01A) -1599 2877 1240 30 
H(01B) 34 3464 1599 30 
H(014) 5421 2495 2588 26 
H(015) 590 2501 2568 27 
H(016) 3237 2819 1314 24 
H(01C) -5807 2118 -1193 37 
H(01D) -4814 1570 -1747 37 
H(01E) 3409 2493 4082 31 
H(01F) 4015 1820 3660 31 
H(021) 1249 3427 3505 39 
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H(023) 6826 3519 2367 39 
H(024) -3639 2454 -2607 33 
H(025) 3915 5178 3026 48 
H(02A) -12293 3746 -4620 38 
H(02B) -11155 3975 -5408 38 
H(028) 1172 4559 3569 46 
H(02C) -3333 3512 214 42 
H(02D) -2022 3783 -510 42 
H(03A) -10444 3082 -3634 35 
H(03B) -8225 3531 -3440 35 
H(031) -7997 3059 -1443 42 
H(033) -5144 4615 152 39 
H(035) 1614 5447 1505 43 
H(037) -6223 4946 -1595 57 
H(038) 1517 4409 941 43 
H(039) -8443 2282 -2614 27 
H(040) -2649 3552 -2583 46 
H(041) -12904 4628 -3789 37 
H(042) -5040 5656 707 43 
H(043) -8580 4154 -1160 50 
H(044) 6781 4651 2455 46 
H(045) -6054 5598 -4121 52 
H(046) -7111 4612 -4787 46 
H(047) -1651 6082 1395 48 
H(048) -8447 6094 -3279 52 
H(049) -11894 5611 -3127 45 
H(050) -3273 4646 -2298 56 
 
Table A2.1.6. Torsion angles [°] for 101 
________________________________________________________________ 
C(036)-O(1)-C(011)-C(030) -145.1(3) 
C(036)-O(1)-C(011)-C(039) -22.0(4) 
C(029)-O(9)-C(013)-C(016) 174.7(3) 
C(023)-C(009)-C(014)-C(019) 117.9(4) 
C(021)-C(009)-C(014)-C(019) -63.5(4) 
C(023)-C(009)-C(014)-C(015) -116.1(4) 
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C(021)-C(009)-C(014)-C(015) 62.6(5) 
C(020)-O(4)-C(015)-C(014) -110.5(3) 
C(020)-O(4)-C(015)-C(016) 11.5(4) 
C(009)-C(014)-C(015)-O(4) 178.4(3) 
C(019)-C(014)-C(015)-O(4) -55.3(4) 
C(009)-C(014)-C(015)-C(016) 61.8(4) 
C(019)-C(014)-C(015)-C(016) -171.8(3) 
C(020)-O(3)-C(016)-C(013) -147.0(3) 
C(020)-O(3)-C(016)-C(015) -26.1(4) 
O(9)-C(013)-C(016)-O(3) -68.0(4) 
O(9)-C(013)-C(016)-C(015) 176.4(3) 
O(4)-C(015)-C(016)-O(3) 9.1(4) 
C(014)-C(015)-C(016)-O(3) 130.5(3) 
O(4)-C(015)-C(016)-C(013) 127.5(3) 
C(014)-C(015)-C(016)-C(013) -111.1(4) 
C(009)-C(014)-C(019)-C(034) -74.7(4) 
C(015)-C(014)-C(019)-C(034) 159.9(3) 
C(015)-O(4)-C(020)-O(3) -27.7(4) 
C(015)-O(4)-C(020)-C(96) -143.0(3) 
C(015)-O(4)-C(020)-C(95) 91.5(4) 
C(016)-O(3)-C(020)-O(4) 33.6(4) 
C(016)-O(3)-C(020)-C(96) 149.7(3) 
C(016)-O(3)-C(020)-C(95) -86.4(3) 
C(023)-C(009)-C(021)-C(028) 0.0(6) 
C(014)-C(009)-C(021)-C(028) -178.7(3) 
C(024)-C(017)-C(022)-O(8) -33.6(6) 
C(024)-C(017)-C(022)-O(7) 149.8(4) 
C(021)-C(009)-C(023)-C(044) 0.7(6) 
C(014)-C(009)-C(023)-C(044) 179.4(4) 
C(040)-C(018)-C(024)-C(039) -114.9(4) 
C(031)-C(018)-C(024)-C(039) 62.4(5) 
C(040)-C(018)-C(024)-C(017) 123.3(4) 
C(031)-C(018)-C(024)-C(017) -59.5(5) 
C(022)-C(017)-C(024)-C(018) -72.0(4) 
C(022)-C(017)-C(024)-C(039) 165.4(3) 
C(030)-O(10)-C(026)-C(027) 67.0(4) 
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O(10)-C(026)-C(027)-C(041) -125.8(4) 
O(10)-C(026)-C(027)-C(046) 52.8(5) 
C(009)-C(021)-C(028)-C(025) 0.1(6) 
C(044)-C(025)-C(028)-C(021) -0.8(6) 
C(013)-O(9)-C(029)-C(032) 72.9(4) 
C(026)-O(10)-C(030)-C(011) 170.9(3) 
O(1)-C(011)-C(030)-O(10) -63.9(4) 
C(039)-C(011)-C(030)-O(10) -177.3(3) 
C(040)-C(018)-C(031)-C(043) 1.7(6) 
C(024)-C(018)-C(031)-C(043) -175.6(3) 
O(9)-C(029)-C(032)-C(038) 18.2(6) 
O(9)-C(029)-C(032)-C(033) -164.4(4) 
C(038)-C(032)-C(033)-C(042) -0.4(6) 
C(029)-C(032)-C(033)-C(042) -178.0(4) 
C(014)-C(019)-C(034)-O(6) -20.0(6) 
C(014)-C(019)-C(034)-O(5) 161.7(3) 
C(039)-O(2)-C(036)-O(1) 25.3(4) 
C(039)-O(2)-C(036)-C(97) 142.2(3) 
C(039)-O(2)-C(036)-C(98) -92.8(4) 
C(011)-O(1)-C(036)-O(2) -0.7(4) 
C(011)-O(1)-C(036)-C(97) -117.5(3) 
C(011)-O(1)-C(036)-C(98) 118.2(3) 
C(047)-C(035)-C(038)-C(032) -0.5(7) 
C(033)-C(032)-C(038)-C(035) 0.7(6) 
C(029)-C(032)-C(038)-C(035) 178.2(4) 
C(036)-O(2)-C(039)-C(011) -38.4(4) 
C(036)-O(2)-C(039)-C(024) -162.0(3) 
O(1)-C(011)-C(039)-O(2) 36.2(3) 
C(030)-C(011)-C(039)-O(2) 152.9(3) 
O(1)-C(011)-C(039)-C(024) 153.5(3) 
C(030)-C(011)-C(039)-C(024) -89.8(4) 
C(018)-C(024)-C(039)-O(2) 178.9(3) 
C(017)-C(024)-C(039)-O(2) -57.3(4) 
C(018)-C(024)-C(039)-C(011) 65.1(4) 
C(017)-C(024)-C(039)-C(011) -171.1(3) 
C(031)-C(018)-C(040)-C(050) -1.9(6) 
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C(024)-C(018)-C(040)-C(050) 175.5(4) 
C(046)-C(027)-C(041)-C(049) 1.7(6) 
C(026)-C(027)-C(041)-C(049) -179.6(4) 
C(032)-C(033)-C(042)-C(047) -0.1(7) 
C(050)-C(037)-C(043)-C(031) -0.5(7) 
C(018)-C(031)-C(043)-C(037) -0.6(6) 
C(028)-C(025)-C(044)-C(023) 1.4(6) 
C(009)-C(023)-C(044)-C(025) -1.4(7) 
C(048)-C(045)-C(046)-C(027) 0.9(6) 
C(041)-C(027)-C(046)-C(045) -1.6(6) 
C(026)-C(027)-C(046)-C(045) 179.8(4) 
C(038)-C(035)-C(047)-C(042) 0.0(7) 
C(033)-C(042)-C(047)-C(035) 0.3(7) 
C(046)-C(045)-C(048)-C(049) -0.3(6) 
C(045)-C(048)-C(049)-C(041) 0.5(6) 
C(027)-C(041)-C(049)-C(048) -1.2(6) 
C(043)-C(037)-C(050)-C(040) 0.4(7) 
C(018)-C(040)-C(050)-C(037) 0.9(7) 
________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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A2.1.7. ORTEP diagrams of 101 
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